

AWARD NUMBER: Y1FY PHEEGJG

TITLE: Microvascularized 3D Breast Cancer Constructs for Drug Testing and Development

PRINCIPAL INVESTIGATOR: Joel L. Berry, Ph.D.

CONTRACTING ORGANIZATION: The University of Alabama at Birmingham
Oa{ a * @e EISA GI

REPORT DATE: October 2014

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

| | | | | | |
|---|--------------------|---------------------------------|-----------------------------------|--|--|
| 1. REPORT DATE October 2014 | | 2. REPORT TYPE Annual | | 3. DATES COVERED 30 Sep 2013 - 29 Sep 2014 | |
| 4. TITLE AND SUBTITLE Microvascularized 3D Breast Cancer Constructs for Drug Testing and Development | | | | 5a. CONTRACT NUMBER | |
| | | | | 5b. GRANT NUMBER W81XWH-13-1-0292 | |
| | | | | 5c. PROGRAM ELEMENT NUMBER | |
| 6. AUTHOR(S) Joel L. Berry, Ph.D. Email: jlberry@uab.edu | | | | 5d. PROJECT NUMBER | |
| | | | | 5e. TASK NUMBER | |
| | | | | 5f. WORK UNIT NUMBER | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Alabama at Birmingham Birmingham, AL 35294 | | | | 8. PERFORMING ORGANIZATION REPORT NUMBER | |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 | | | | 10. SPONSOR/MONITOR'S ACRONYM(S) | |
| | | | | 11. SPONSOR/MONITOR'S REPORT NUMBER(S) | |
| 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited | | | | | |
| 13. SUPPLEMENTARY NOTES | | | | | |
| 14. ABSTRACT Embodiments of the present disclosure provide for three-dimensional (3D), prevascularized, engineered tissue constructs, 3D prevascularized engineered tissue models of cancer, and bioreactors and bioreactor arrays including the tissue constructs. The present disclosure also provides methods of making the tissue constructs, methods of using the tissue constructs, methods of drug discovery using the tissue constructs and/or cancer models, and the like. | | | | | |
| 15. SUBJECT TERMS- nothing listed | | | | | |
| 16. SECURITY CLASSIFICATION OF: | | | 17. LIMITATION OF ABSTRACT | 18. NUMBER OF PAGES | 19a. NAME OF RESPONSIBLE PERSON |
| a. REPORT | b. ABSTRACT | c. THIS PAGE | | | USAMRMC |
| U | U | U | UU | 92 | 19b. TELEPHONE NUMBER (include area code) |

Table of Contents

| | <u>Page</u> |
|---|-------------|
| 1. Introduction..... | 1 |
| 2. Keywords..... | 1 |
| 3. Overall Project Summary..... | 1 |
| 4. Key Research Accomplishments..... | 4 |
| 5. Conclusion..... | 4 |
| 6. Publications, Abstracts, and Presentations..... | 5 |
| 7. Inventions, Patents and Licenses..... | 5 |
| 8. Reportable Outcomes..... | 5 |
| 9. Other Achievements..... | 6 |
| 10. References..... | 6 |
| 11. Appendices..... | 7 |

INTRODUCTION:

The project plan is to develop a three-dimensional (3D) microvascularized *in vitro* model system for breast cancer that could be used to culture individual cancer cells from patients and permit testing of a panel of chemotherapeutics. The research project will develop a new approach for drug efficacy testing that can better predict *in vivo* responses to therapeutics than current *in vitro* preclinical models. There are two aims. In the first, a microphysiologic, microvascularized 3D breast cancer model system that incorporates breast cancer-associated fibroblasts (CAFs), microvascular endothelial cells (ECs), and cancer epithelial cells, embedded in extracellular matrix (ECM) supported by a novel carbon foam (reticulate vitreous carbon [RVC]) scaffold that contains EC-lined microchannels, will be assembled using breast cancer cell lines and characterized. In Aim 2, epithelial and stromal cells from cancer tissues from patients will be incorporated into the model system and parameters adjusted to achieve a microscopic architecture and representative molecular subtype of the originating cancer.

KEYWORDS:

Breast cancer, microphysiologic, drug development, fibroblasts, extracellular matrix, in vitro model

OVERALL PROJECT SUMMARY:

The laboratories of Dr. Frost and Berry work closely and coordinately to achieve the goals of the project. We communicate with each other frequently via e-mail or phone and have joint bi-weekly meetings. However, we have indicated for each Objective which PI is primarily responsible for the work described, although both investigators have contributed to each Objective. We have made significant progress in the development of our perfused breast cancer surrogate over this first year of funding. All data presented below is not yet published and we request that it not be disseminated prior to publication.

Task #1. Assemble constructs of ECM and microchannels with endothelial cells in a 12-well format and vary microchannel diameter and flow rates to maintain endothelialization and perfusion of microchannels for 4 weeks

A. Current Objective: Redesign of bioreactor system (Berry and Frost)

The original bioreactor design was prone to leaks, did not allow easy visualization of cellular content and was somewhat difficult to assemble. After several design iterations, we have a new, improved design detailed below. Although necessary, this bioreactor/surrogate optimization (detailed below) has delayed progress in this Task somewhat.

Results, Progress and Accomplishments:

We have designed and are manufacturing a revised bioreactor that performs controlled perfusion of engineered breast cancer surrogates. Residing within the bioreactor is the cancer surrogate consisting of breast cancer epithelial cells (either MDA-MB-231 or MCF7 cells), breast cancer associated fibroblasts (CAF), extracellular matrix (ECM) consisting of collagen I and Matrigel (basement membrane material (BM)), a rigid and porous structure to support the viscous ECM and the cells that will grow within the ECM. We have also developed a technique for creating microchannels to penetrate the surrogate.

Progress – Two positive developments have resulted. The first (overseen primarily by Dr. Frost) is that we have identified and developed a novel technique for fabricating porous silicone foam (PDMS) (**Figure 1A**) that will act as a support for the relatively fluid ECM gel and to replace the reticulate vitreous carbon foam (RVC, **Figure 1B**). This is positive because it will facilitate histologic sectioning with a reduction in sectioning artifacts that are characteristic of the RVC, and the PDMS foam is optically clear which allows better visualization of the cellular contents of the surrogate than the opaque RVC. The second development (overseen primarily by Dr. Berry) is a bioreactor design that is significantly easier to use, has fewer connecting parts to leak, and allows more control and reproducibility in our experiments (**Figure 2**). This design can also be assembled in a 12 well format.




Figure 1. PDMS Foam (A) and RVC foam (B). PDMS is inert, optically clear, and sections more easily with a microtome as opposed to RVC which is opaque a difficult to section.




Figure 2. CAD renderings of our new bioreactor. The cell/ECM/PDMS foam, perforated with microchannels, will be loaded into the tissue chamber and perfused with culture medium.

- B. Current Objective:** Characterization of microchannel size, flow/shear stress, and permeability (Berry)
Results, Progress and Accomplishments: The stability of the sizes (diameters) of microchannels penetrating the breast cancer surrogate was assessed and a shear stress associated with flow through the channels was calculated. The details of this analysis are presented in the attached submitted manuscript, which has received a favorable review and is under revision (minor). Assessment of microchannel permeability in the system without cells is currently underway.
- C. Current Objective:** To line microchannels by human microvascular endothelial cells (Frost and Berry)
Results, Progress and Accomplishments: Initial attempts to line the microchannels with endothelial cells have utilized endothelial cells isolated from rat brains and have helped us in developing our methods. Using these cells, we have achieved partial lining of microchannels (**Figure 3**) (Berry), but have experienced some difficulty in maintaining their viability over time. We are currently working to improve this by optimizing medium, flow rates, etc. Because our surrogate is intended to be a relevant human system, we have purchased (Berry) primary human mammary microvascular endothelial cells, successfully expanded these cells (Frost) and they are currently being immortalized for continued future use by transduction to over-express hTERT (Frost).




Figure 3. H&E-stained histologic section of ECM/RVC construct with microchannels. Endothelial cells (arrows) are attached to the microchannel wall and are demonstrating flattening and spreading, indicating adhesion and viability

Task #2. Assemble complete microvascularized 3D constructs to achieve a microscopic architecture that is analogous to most human carcinomas by varying the quantity and ratio of cancer epithelial cells and CAF, the ECM (collagen I, basement membrane or a combination) and media formulation

A. Current Objective: Immortalize human breast cancer associated fibroblasts (CAF) for long-term and ease of use in our system (Frost).

Results, Progress and Accomplishments: We have previously isolated CAF from multiple different individuals. 3 CAF were transduced to express hTERT. Increased expression of hTERT was confirmed by quantitative RT-PCR and the growth of these cells (CAF-hTERT) thus far has been continuous and the rate of growth increased.

B. Current Objective: Adjust ECM composition, cell number, medium formulation, and ratio of cancer epithelial cells to fibroblasts to maximize cell aggregation (analogous to human breast cancer) and viability (Frost and Berry)

Results, Progress and Accomplishments: We are currently performing experiments to assess the effect of increasing concentrations of collagen I on the aggregation and viability of the CAF and breast cancer epithelial cells. We have found that a collagen concentration of 6 and 8 mg/ml (bovine collagen) provides optimal cell viability, while collagen concentration (from 1.9 to 8.0 mg/ml) had no significant effect on aggregation of cells (**Figure 4**). Viability was assessed by autofluorescence in histologic sections of the breast cancer surrogates, as described in the appended submitted manuscript. This will be supplemented by Ki67-labeling as an indicator of proliferation.




Figure 4. MDA-MB-231 and CAF-hTERT were co-cultured in ECM containing increasing concentrations of collagen I, either bovine or rat tail, in solid cultures without microchannels/perfusion for 7 days. Viability (A) was assessed by autofluorescence as described in the appended manuscript. Aggregation (B) was assessed by image processing using Image J software.

We are currently comparing the effect on the growth (standard growth curves of monolayer cultures) of CAF, MDA-MB-231, MCF7 and our endothelial cells) of 4 - 5 different medium formulations to select the best for our perfused surrogates. We are also assessing different methods of incorporating the cells into the ECM for optimal aggregation and viability, as well as assessing the ratio of CAF to breast cancer epithelial cells to achieve a result that is consistent with that found in human breast carcinomas. A manuscript describing these methods to optimize the ECM and cellular constituents of our surrogate is in preparation.

Task #3. Assess viability of cancer epithelial cells and maintenance of molecular subtype over 4 weeks

A) Current Objective: To incrementally extend the duration of cultures (CAF-hTERT and MDA-MB-231 cells in ECM) in the bioreactor and assess viability and proliferation.

Results, Progress and Accomplishments: Thus far for this Task, we have utilized a previous design of our bioreactor system (as described in the appended manuscript) and anticipate even better performance with the new version that will be rolled out soon. We are comparing the viability results among three groups: 1) solid surrogates without microchannels or perfusion and not maintained in the bioreactor, 2) cultures in the bioreactor, with microchannels, but without perfusion (flow) through the channels, 3) cultures in the bioreactor with microchannels and perfusion. These surrogates do not yet include endothelial cells. Comparison of viability results for surrogates maintained for one week are included in the appended manuscript. Surrogates maintained in the bioreactor with perfusion demonstrated the greatest level of cell survival and provided evidence that our novel system can maintain long-term viability of cells grown in 3D. We have very recently maintained surrogates for 2 weeks with good viability and even cell expansion on H&E-stained histologic sections (**Figure 5**). Analyses of viability, proliferation and cell aggregation of these surrogates are underway.




Figure 5. Photomicrographs (200x) of FFPE breast cancer surrogates consisting of MDA-MB-231 and CAF-hTERT in ECM and with perfused microchannels. The surrogates were grown in the bioreactor for 1 week (A) and 2 weeks (B). Note the increase in cell density/number over time.

KEY RESEARCH ACCOMPLISHMENTS:

- Development of a perfusion bioreactor system that will maintain a 3D breast cancer surrogate, currently consisting of ECM, breast cancer epithelial cells and CAF, for at least 2 weeks.
- Development of multiple immortalized CAF cell lines.

CONCLUSION: There is a great need for preclinical testing systems that better predict efficacy, safety, and pharmacokinetics of cancer therapies prior to human clinical trials. An approach to the development of better, predictive in vitro systems is to more closely recapitulate the cellular and spatial complexity of human cancers. One limitation of using current in vitro systems to model cancers is the lack of an appropriately large volume to accommodate the development of this complexity over time. The distinctive contribution emerging as a result of our project is the bioreactor technology that we have shown allows for flow perfusion and continued viability of breast cancer cells (epithelial cells and fibroblasts) coupled with microvascular endothelial cells in a larger volume (1.2 cm³) than is currently possible. These cells exist in an extracellular matrix material that will allow all cell types to accurately mimic breast cancer morphology and biology in vitro. Upon demonstration of viability and function of this living tissue surrogate after 4 weeks, we will introduce a variety of anti-cancer drugs in order to discern efficacy of these drugs as an example of how this system could be used as a platform for drug development. The far-reaching implications of this outcome are that the system 1) may be used for testing drugs on individual cancer cells derived from breast cancer patients (i.e., personalized medicine) and 2) will enhance the efficacy and speed of pre-clinical drug development.

Over the next year, we will deploy and evaluate the new bioreactor design and continue the experiments to optimize the lining of microchannels by endothelial cells, including quantification of endothelial cell confluence, viability, phenotypic expression and barrier function. We will also quantify the diffusivity of large molecules (FITC-labeled dextran) in the collagen/matrigel mixture. Experiments involving stimulation of angiogenesis will be undertaken in the next reporting period. In addition, we will continue to optimize surrogate constituents to better recapitulate human breast carcinomas morphologically, assess our ability to

maintain surrogates in the long-term and construct and evaluation surrogates with all cellular components, including endothelial cells.

PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

Lay Press: None

Peer-Reviewed Scientific Journals:

LE Marshall, K Goliwas, L Miller, A Penman, AR Frost, JL Berry. Flow-perfusion bioreactor system for engineered breast cancer surrogates to be used in preclinical testing. 2014. *Journal of Tissue Engineering and Regenerative Medicine*. (manuscript under minor revision)

Invited Articles: None

Abstracts:

Marshall LE, Goliwas KA, Frost AR, Penman A, Murphy-Ullrich J, Wick T, Berry JL. Microvascularization of Three-Dimensional Breast Cancer Constructs for Drug Testing and Development. Podium presentation at the 2014 World Congress of Biomechanics, Boston, Massachusetts, July 2014.

Marshall LE, Frost AR, Berry JL. Use of a Perfusion Flow Bioreactor System to Vascularize 3D Scaffold Microchannels. Podium and poster presentations at the 3rd Annual UAB Biomedical Engineering Symposium, Birmingham, AL, April 2014.

Marshall LE, Frost AR, Berry JL. Microvascularized 3D Breast Cancer Constructs for Drug Testing and Development. Podium presentation at Graduate Student Research Day, Birmingham, AL, March 2014

Goliwas KA, Marshall L, Yuan K, Berry JA, Frost AR. Modeling Breast Cancer in 3D. Poster presentation at the UAB Comprehensive Cancer Center Retreat, November 4, 2013.

Goliwas KA, Marshall L, Yuan K, Berry JA, Frost AR. Importance of ECM and media permeation in 3D modeling of breast cancer. Poster presentation at the national meeting of the American Association for Cancer Research, San Diego, CA, April 7, 2014. Published in *Proc Am Assoc Cancer Res* (Abstract #2022) 2014

Goliwas KA, Marshall L, Yuan K, Berry J, Frost AR. Modeling Breast Cancer in 3D. Poster Presentation at UAB Pathology Research Day, October 18, 2013

INVENTIONS, PATENTS AND LICENSES: List all patents and licenses applied for and/or issued. Each entry must include the inventor(s), invention title, patent application number, filing date, patent number if issued, patent issued date, national, or international.

Patent application filed March 26, 2013

Applicant name: The UAB Research Foundation

Patent application title: *Three-Dimensional, Prevascularized, Engineered Tissue Constructs, Methods Of Making and Methods of Using the Tissue Constructs*

International Application Number: PCT/US13/29366

No licenses have resulted from this patent application.

REPORTABLE OUTCOMES: Provide a list of reportable products that have resulted from this research. Products are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment

and / or rehabilitation of a disease, injury or condition, or to improve the quality of life. This list may include development of prototypes or similar products that may be commercialized.

- A technique for fabricating porous silicone foam (PDMS) that acts as a support for the relatively fluid ECM gel
- A revised bioreactor design (and bioreactor) that is significantly easier to use and allows more control and reproducibility in our experiments
- Immortalized breast CAF cell lines

OTHER ACHIEVEMENTS:

- This funding is supporting the training and development of two outstanding graduate students – one in Bioengineering (Lauren Marshall, 4th year graduate studies) and one in Graduate Biomedical Sciences, Cancer Biology theme (Kayla Goliwas, 3rd year graduate studies). Lauren has completed her Master’s coursework and her qualifying exam for her PhD. Kayla will soon be taking her qualifying examination for PhD.
- This project has also provided laboratory training for 3 undergraduate students working under the mentorship of PI Berry and graduate student Lauren Marshall.
- Our experiences in this project helped us to devise perfused, 3D models of breast ductal carcinoma in situ (DCIS) which are the basis for another project that was recently (October 22, 2014) submitted to the NIH for potential funding as an R21 (*Biomechanics of the Stromal Regulation of DCIS*, Berry and Frost are Co-PIs).

REFERENCES:

Pertinent references are provided in the attached manuscript.

APPENDICES:

Manuscript - Appendix I

Provisional patent application – Appendix II

Title: Flow-perfusion bioreactor system for engineered breast cancer surrogates to be used in preclinical testing

Authors: Lauren E. Marshall, Kayla F. Goliwas, Lindsay M. Miller, Andrew D. Penman, Andra R. Frost, and Joel L. Berry

Keywords: bioreactor; 3D breast cancer model; stroma; perfusion; microchannels

Lauren E. Marshall, M.S.

Department of Biomedical Engineering

The University of Alabama at Birmingham

877 Shelby Interdisciplinary Biomedical Research Building

1825 University Boulevard

Birmingham, Alabama 35294

telephone: (205) 934-8410

fax: (205) 975-4919

email: lemarsh@uab.edu

Kayla F. Goliwas, B.S.

Department of Pathology

The University of Alabama at Birmingham

320B Wallace Tumor Institute

1824 6th Avenue South

Birmingham, Alabama 35233

telephone: (205) 934-2746

fax: (205) 934-5499

email: kgoli12@uab.edu

Lindsay M. Miller, B.S.

Department of Biomedical Engineering

The University of Alabama at Birmingham

877 Shelby Interdisciplinary Biomedical Research Building

1825 University Boulevard

Birmingham, Alabama 35294

telephone: (205) 934-8410

fax: (205) 975-4919

email: lmm6@uab.edu

Andrew D. Penman, Ph.D. FRSC

Southern Research Institute

2000 Ninth Avenue South

P.O. Box 55305

Birmingham, AL 35205-5305

telephone: (205) 581-2712

fax: (205) 581-2044

email: penman@southernresearch.org

Andra R. Frost, M.D.

Department of Pathology

The University of Alabama at Birmingham

320B Wallace Tumor Institute

1824 6th Avenue South

Birmingham, Alabama 35233

telephone: (205) 934-2746

fax: (205) 934-5499

email: afrost@uab.edu

Joel L. Berry, Ph.D. (corresponding author)

Department of Biomedical Engineering

The University of Alabama at Birmingham

802 Shelby Interdisciplinary Biomedical Research Building

1825 University Boulevard

Birmingham, Alabama 35294

telephone: (205) 996-9661

fax: (205) 975-4919

email: jlberry@uab.edu

Abstract

There is a need for preclinical testing systems that better predict efficacy, safety, and pharmacokinetics of cancer therapies prior to human clinical trials. An approach to the development of predictive *in vitro* systems is to more closely recapitulate the cellular and spatial complexity of human cancers. One limitation of using current *in vitro* systems to model cancers is the lack of an appropriately large volume to accommodate the development of this complexity over time. To address this limitation, we have designed and constructed a novel flow-perfusion bioreactor system that can support tissue engineering of larger volume, multi-cellular cancer surrogates by adapting current microfluidic devices. Key features of this technology are a three-dimensional volume (1.2 cm³) that has more depth than utilized in existing microfluidic systems and a means to perfuse the volume, enabling development of realistic tumor geometry. The constructs were fabricated by infiltrating porous carbon foams with an extracellular matrix hydrogel and engineering through-microchannels. The carbon foams structurally supported the hydrogel and microchannel patency up to 161 hours. The extracellular matrix hydrogel was shown to adhere to the carbon foam and polydimethylsiloxane flow chamber, which housed the hydrogel/carbon foam construct, when surfaces were coated with glutaraldehyde (carbon foam) and nitric acid (polydimethylsiloxane). Additionally, the presence of perfused microchannels was shown to better support the viability of breast cancer cells and fibroblasts for seven days in comparison to similar preparations without microchannels or perfusion. Therefore, the flow-perfusion bioreactor system supports cell viability in volume and stromal contexts that are physiologically-relevant.

1. Introduction

Three-dimensional multi-cellular cultures perfused in microfluidic systems are promising technologies for drug development (Maguire *et al.*, 2009). The importance of these systems is underscored by participation of the United States National Institutes of Health, Defense Advanced Research Projects Agency, the Food and Drug Administration, universities and biotechnology industries in their development. Rapid, accurate, and inexpensive assessment of drug efficacy, toxicity, and pharmacokinetics prior to first-in-human studies is the primary goal. These efforts are motivated by the need to extend traditional two-dimensional (2D) cell culture systems into three-dimensional (3D) environments that better replicate the microphysiologic environment of breast cancer and more accurately predict drug efficacy and toxicity (Li *et al.*, 2010, Sharma *et al.*, 2010). Herein, we describe the development of a novel 3D flow-perfusion bioreactor system to support tissue engineering of a multi-cellular breast cancer surrogate that would ultimately serve as a drug development platform for cancer therapeutics. Two key features of this technology are a 3D volume which is larger than that utilized in existing microfluidic systems and the ability to perfuse this volume.

Lab-on-a-chip microfluidic devices, a type of flow-perfusion bioreactor system, have recently been employed to study the relationship between cell types, extracellular matrix (ECM), diffusion, and shear stress (Buchanan *et al.*, 2014, Park *et al.*, 2010, Zheng *et al.*, 2012). Key features of the lab-on-a-chip devices are a transparent support structure enabling fluorescence and confocal imaging of fluid flow and cellular phenotypes as well as precise control over the geometry of flow microchannels (Barrila *et al.*, 2010, Hielscher and Gerecht, 2012). These devices are easily fabricated using soft lithography, require small volumes of media for perfusion, and facilitate parallel experimentation. Moreover,

these lab-on-a-chip perfusion systems allow for insertion of only small volumes of ECM hydrogels (e.g. collagen) as substrates for epithelial cell growth whilst microchannel diameter and chip thickness typically do not exceed 100 μm and 500 μm , respectively. These factors make the lab-on-a-chip approach well suited for microscopic visualization of flow and cellular events (Park *et al.*, 2010, Zheng *et al.*, 2012).

Breast cancer tumor volume is an important consideration in accurate modeling of breast cancers. As an example, triple negative breast cancers average 4.1 ± 2.7 cm in diameter (Chen *et al.*, 2007). Thus, *in vitro* systems designed to replicate breast tumor biology require larger volumes than lab-on-a-chip systems allow. Thicker microphysiologic perfusion systems within flow-perfusion bioreactors have recently demonstrated ease of visualization and maintenance of cellular phenotype in the presence of well-defined flow characteristics (Buchanan *et al.*, 2014). Buchanan showed that breast carcinoma cells embedded in rat tail collagen I and perfused through a central endothelialized channel (711 μm in diameter) maintained their viability for up to 72 hours of culture. Additionally, a study by Chen *et al.* (2010) showed that perfusion (800 μm x 90 μm rectangular channel) over alginate-encapsulated breast tumor cells led to cellular aggregation after five days of culture; these cultures were maintained up to two weeks in a microfluidic device. However, many of the 3D *in vitro* models of breast cancer to date have relied upon cell spheroids in suspension or cell aggregation in ECM volumes that do not recapitulate relevant volumes of *in vivo* breast tumors and/or lack relevant stromal components such as fibroblasts (Petersen *et al.*, 2003, Shaw *et al.*, 2004). Most of the 3D models that have used greater, more relevant, solid volumes have not supported long term viability of incorporated cells, presumably a result of inadequate perfusion of nutrients and oxygen.

In addition to the volume required for tumor growth, the structural organization of tumor epithelial and stromal cells (e.g., cancer-associated fibroblasts) within the ECM volume supports relevant gene expression and cellular phenotype and influences drug sensitivity (Astashkina *et al.*, 2012, Schanz *et al.*, 2010, Weigelt and Bissell, 2008). Since viability of cells embedded in the 3D tumor construct is dependent upon the model thickness and since oxygen diffusion distance is less than 100-200 μm , it is essential that perfusion is provided that will support tissue oxygenation (Gibot *et al.*, 2010, Hielscher and Gerecht, 2012, Rouwkema *et al.*, 2008, Schanz *et al.*, 2010, Sukmana, 2012) in biologically relevant 3D models.

The flow-perfusion bioreactor system described here is designed to support the viability of human breast cancer cells and breast fibroblasts in an *in vitro* 3D construct with a more physiologically-relevant volume. The goal of this technology is to provide 3D humanized, engineered breast tumor models to supplement *in vivo* animal studies where interspecies differences in physiology, drug metabolism, and mechanistic responses to disease clearly do not reflect safety and toxicity results observed in human clinical trials (Astashkina *et al.*, 2012, Barrila *et al.*, 2010, Gupta and Kuperwasser, 2004, Haycock, 2011, Schanz *et al.*, 2010).

2. Methods and Materials

A key component of our flow-perfusion bioreactor system for breast cancer is a 3D construct that was designed as a relatively thick volume ($>500 \mu\text{m}$) to support long-term cell maintenance and growth, recapitulate physiologic cell function, and accurately model responses to external challenges (i.e., drug). Key elements of our system are prefabricated

perfusion microchannels, a thickness of 2.4 mm, structural support for the ECM containing breast cancer cells and stromal fibroblasts, ease of handling, and potential for multiplexing.

2.1 3D construct fabrication and measurement of carbon foam purity and microchannel size

The 3D constructs are composed of ECM proteins supported by an inert backbone and perforated with microchannels. Bovine collagen I (BD Biosciences) (1.9 mg/ml) and growth-factor reduced Matrigel (BD Biosciences), in a 9:1 (v/v) ratio, were chosen as the ECM components to mimic the ECM in the breast cancer microenvironment (Lochter and Bissell, 1995). The low viscosity of the ECM necessitated a structure to support prefabricated microchannel patency and to minimize shrinkage of the ECM hydrogel. A rigid carbon foam (reticulated vitreous carbon (RVC), ERG Aerospace Corporation or Ultramet) was chosen as it is stiff, autoclavable, and highly porous (approximately 500 μm pore size) (**Figure 1A**) (Pec *et al.*, 2010, Wickham *et al.*, 1983). Energy dispersive x-ray spectroscopy (EDS) with an EDAX detector (Ametek, SEM; Quanta FEG 650, FEI) was used to measure carbon purity. Importantly, since the 3D constructs are thicker than the diffusion distance of oxygen (100-200 μm), microchannels serve as conduits for oxygenated media perfusion and thus enabled oxygen and nutrients from the media to diffuse throughout the ECM hydrogels.

Microchannels were formed by insertion of Teflon-coated stainless steel rods through the carbon foam prior to injection of the ECM hydrogel prepolymer (**Figure 1B**). The ECM hydrogel solution contained 13.7% (v/v) of DMEM medium, 1.9 mg/ml of bovine collagen I, 10% (v/v) of 10X DMEM medium, 10% (v/v) of GFR Matrigel and 0.524 M of sodium bicarbonate (Thermo Scientific). This final collagen concentration was

chosen to maintain a balance between the matrix stiffness necessary to withstand the pressures of fluid flow and the ability of cells to migrate through pores in the ECM hydrogel (Carey *et al.*, 2012). Polymerization occurred in the incubator (37°C, 5% CO₂) over 45 minutes. After ECM hydrogel polymerization, rods were removed, resulting in parallel microchannels (250 and 400 μm diameter).

To measure the shrinkage or enlargement of microchannels over time, microchannels were formed in ECM hydrogels with and without carbon foam support and microchannel diameters were measured over time. The constructs with microchannels were maintained in DMEM 1x (Cellgro) medium supplemented with 10% Fetal Bovine Serum (FBS, HyClone Laboratories) without perfusion. Five to fifteen microchannels were followed from 10 minutes to 161 hours post-polymerization and imaged using bright field microscopy (100X total magnification). Microchannel diameters were compared to original microchannel-forming rod diameters (i.e., 400 μm) using ImageJ software (**Figure 2**).

2.2 Measurement of material wettability

A polydimethylsiloxane (PDMS) flow chamber was fabricated to house the 3D construct (**Figure 1C**). It was necessary to determine wettability between the ECM hydrogel and the PDMS and between the ECM hydrogel and the carbon foam to ensure proper sealing in the flow chamber. PDMS sheets were fabricated by mixing an elastomer base and curing agent (Sylgard) in a 10:1 ratio. After autoclave sterilization, sheets were treated with either 63 wt% nitric acid or 25% (v/v) glutaraldehyde and rinsed in phosphate buffered saline (PBS). Untreated sheets acted as the negative control. A 15 μL droplet of water or pre-polymerized ECM hydrogel (as previously prepared) was deposited onto each PDMS sheet at room temperature. The camera (Keyence Digital Microscope VHX-600 or Panasonic

LumixDMC-ZS19) was placed in line with the PDMS sheets where side-view images were captured in 45 second intervals. This process was repeated for each surface treatment in triplicate for both water and ECM hydrogel. Contact angles were measured at the ECM hydrogel-PDMS interface on both sides of the droplet using the angle feature in ImageJ software. This process and measurements were repeated on a carbon sheet with the same composition as the carbon foam. Acute contact angles ($\theta \leq 90^\circ$) corresponded to wetting of the ECM hydrogel and PDMS indicating that the hydrophilic surface was sufficient for proper sealing between the two materials. Obtuse contact angles ($\theta \geq 90^\circ$) indicated hydrophobicity of the PDMS.

Tensile testing of a 30 μ l ECM hydrogel droplet was performed to confirm hydrogel adhesion to the PDMS. The droplet was sandwiched between two PDMS sheets attached to the actuator and platform of a dynamic mechanical analyzer (RSA G2, TA Instrument) and allowed to polymerize. Tension was applied at a constant linear rate of 0.25 mm/s until separation of PDMS and ECM occurred. The test was replicated three times and a ten-element, moving average filter was used to find the separation force.

2.3 Design and construction of the flow-perfusion bioreactor

The flow-perfusion bioreactor was designed such that the ECM hydrogel could be polymerized inside the device without contamination or leaks. Transparency of the flow chamber was an additional device feature that enabled microscopic evaluation of samples in real time. The bioreactor device was composed of three pieces: an inlet flow port, an outlet flow port, and a bridge that housed the ECM hydrogels and was made of PDMS (i.e., PDMS flow chamber). PDMS flow chambers were formed in the same manner as PDMS sheets except fabrication occurred in a stainless steel mold (10 mm x 2.4 mm cross-

section). The bioreactor was connected to a media reservoir and a peristaltic pump produced continuous forward-moving flow (**Figure 1C**).

Volumetric flow rates (q) were measured and flow was assumed to be divided equally among the four microchannels, which were embedded in the 3D construct. The average microchannel radius (r) varied between 125 and 200 μm depending on the diameter of the microchannel-forming rods. The Reynold's number (Re), the ratio between inertial to viscous forces that indicates the type of flow (laminar or turbulent), was estimated from the volumetric flow rate through a single microchannel by the equation $Re = 2qpr/\mu A$. The culture media density (ρ) was volumetrically weighed to be approximately 995 kg/m^3 and the microchannel cross-sectional area (A) was derived from the microchannel-forming rod diameter (i.e., $A = 4.9 \times 10^{-4} - 12.6 \times 10^{-4} \text{ cm}^2$). The pressure gradient (Δp), an indicator of the construct's resistance to flow, was measured using $\Delta p = p_{\text{downstream}} - p_{\text{upstream}} = \rho g(H_{\text{downstream}} - H_{\text{upstream}})$ where H is the media height in each Pitot tube. Pitot tubes were fabricated to measure the static pressure across the bioreactor.

2.4 Measurement of cell viability in the bioreactor system

Human breast cancer epithelial cells (MDA-MB-231) were cultured in DMEM supplemented with 10% FBS and 600 $\mu\text{g}/\text{ml}$ G418 (HyClone Laboratories). Fibroblasts were isolated from normal breast (NAF) after IRB approval, as previously described (Sadlonova *et al.*, 2005), and cultured in DMEM supplemented with 10% FBS. MDA-MB-231 cells and NAF were mixed into the ECM hydrogel solution, at a 2:1 ratio. ECM hydrogel polymerization followed as described above. Three different cell/ECM preparations were fabricated: 1) solid without microchannels (2×10^5 MDA-MB-231 cells + 1×10^5 NAF cells/100 μl ECM), 2) with microchannels embedded, but no flow (2×10^6

MDA-MB-231 cells + 1×10^6 NAF cells/100 μ l ECM), and 3) with microchannels embedded and with convective flow (230.6 μ l/min volumetric flow rate, 2×10^6 MDA-MB-231 cells + 1×10^6 NAF cells/100 μ l ECM). Solid cell/ECM preparations were placed in 8-well chamber slides, while microchannel-embedded cell/ECM constructs were prepared in the PDMS flow bioreactor with carbon foam structural support, as described above. All cell/ECM preparations were maintained in low serum media (DMEM + 0.05% FBS) for 1, 3, or 7 days, and subsequently fixed in neutral buffered formalin, processed to paraffin, and sectioned for hematoxylin and eosin (H&E) staining.

Autofluorescence of H&E-stained sections was used to determine viability as previously described (Hennings *et al.*, 2009). Briefly, photomicrographs of H&E-stained sections were acquired (SPOT Flex camera and SPOT basic software 5.0) using bright field (25 ms exposure) and fluorescence (FITC filter set (480 nm excitation), 4000 ms exposure) microscopy (Zeiss Axiovert 35 with PlanF LWD 40x/ 0.60 lens). Each image was corrected to a maximum brightness of 100 and background was subtracted using a rolling ball status of 50 pixels in ImageJ software. Following brightness correction and background subtraction, the intensity of autofluorescence of each cell in the field of view was measured, with at least 100 cells measured per construct. Threshold intensity for determining live versus dead was derived by creating solid cell/ECM (MDA-MB-231 +NAF) preparations using dead cells only, a 50%:50% mix of dead and live cells, and live cells only. Cells were killed by treatment with 0.1 N HCL and heat at 60° C for 2 hours each. Receiver operating characteristic (ROC) analysis was used to identify a pixel intensity cut-off value for live versus dead that provided maximum possible sensitivity (90.3%) and specificity (86.96%) (**Figure 3A**), as previously described (Hennings *et al.*, 2009). Using this pre-established

cut-off (i.e. a pixel intensity of 16), cells in 3D cell/ECM preparations maintained for 1, 3, and 7 days were determined to be living or dead based on the autofluorescence intensity measured. Representative images of autofluorescence from a solid cell/ECM preparation and a construct containing microchannels with convective flow in the bioreactor system, both after 7 days of culture, are shown (**Figure 3B**).

2.5 Statistical analyses

Groups of data representing three values at a minimum were denoted as average \pm standard deviation (SD) or standard error of the mean, when appropriate. Using the Student's t-test assuming unequal variances, differences between two groups were significant at $p < 0.05$. ANOVA single factor test was used for more than two data groups with significance at $p < 0.05$. Statistical analysis was accomplished using the data analysis package for Microsoft Excel or Graphpad Prism 6.

3. Results

The flow-perfusion bioreactor system included a construct consisting of a collagen-Matrigel mixture, supported by an inert carbon foam and featuring pre-fabricated microchannels for perfusion via a connected peristaltic pump. MDA-MB-231 cells and NAF were embedded within the ECM hydrogel and their viability was monitored over time.

3.1 Characterization of the 3D construct components

Two important features of the 3D constructs are the incorporation of carbon foam and microchannels. Elemental mapping of the carbon foam surfaces using EDS exhibited carbon as the primary element with minimal oxygen present at 93.3 and 6.7 wt%,

respectively. A backscatter electron microscopic image showed gray carbon struts with white oxygen deposits (**Figure 1A**). Additionally, microchannels were formed successfully from 400 μm diameter, stainless steel rods and their diameters over time were compared for ECM hydrogels with and without a carbon foam support structure as well as with and without a glutaraldehyde-coating on the microchannel-forming rods. ECM hydrogels were maintained in DMEM medium without flow. At the end of 161 hours, the only microchannels that remained patent were those formed from glutaraldehyde-soaked rods in carbon-supported ECM hydrogel (**Figure 2**). Within 10 minutes of formation, the diameter of the microchannels formed from glutaraldehyde-coated rods was $331 \pm 82 \mu\text{m}$. There was no statistically significant difference in the diameters of these microchannels over the next 161 hours.

3.2 Material wettability

Dynamic contact angle, an indicator of ECM hydrogel wettability to PDMS flow chambers and carbon sheets, was measured for different surface treatments. In particular, the advancing contact angle (maximum angle, θ_{adv}) and the receding contact angle (minimum angle, θ_{rec}) describe rearrangement of atoms inside the liquid and are attributed to surface roughness (Yuan and Lee, 2013). For PDMS sheets, nitric acid surface treatment significantly decreased the contact angle resulting in a more hydrophilic surface (**Table 1**). For carbon sheets, glutaraldehyde surface treatment decreased the contact angle indicating an increase in wettability and a more hydrophilic surface, whereas a nitric acid surface treatment did not significantly change the contact angle (**Table 1**).

A separation force was applied to a PDMS-sandwiched ECM hydrogel droplet. The droplet consistently broke apart near its center before the droplet detached from the PDMS

sheets at 1.43 ± 0.19 mN. This indicated adhesive forces were greater than cohesive forces. A stress-strain relationship was not reported. Comparing the untreated PDMS sheets with surface treated sheets resulted in no significant differences in separation force.

3.3 Laminar flow and pressure gradient measurements

From the volumetrically measured flow rates in a single microchannel, the Reynold's number was found to be significantly smaller than the critical Reynold's number (**Table 2**). Additionally, the pressure gradient was found to be 49 ± 2 Pa (0.37 ± 0.01 mmHg) for maximum fluid flow across the bioreactor.

3.4 Cell viability in co-cultures

Over time, viability of cells in solid cell/ECM preparations (no microchannels) showed a marked decrease, as indicated by an increase in cell autofluorescence. The average percentage of living cells in solid cell/ECM preparations decreased from a mean of 99.76% at day 1 of culture to 32.72% at day 3, and 21.91% at day 7 (**Figure 3C**). The reduced cell viability is most likely due to nutrient deprivation, as previously hypothesized for solid 3D culture systems (Kim *et al.*, 1998). When four 400 μ m diameter microchannels were fabricated in cell/ECM constructs in the bioreactor system, an increase in cell viability compared with solid preparations is seen. However this increase is only statistically significant with perfusion at a volumetric flow rate of 230.6 μ l/min ($p=0.022$, ANOVA). The average percentage of viable cells at day 7 in solid cell/ECM preparations was 21.91% while that in constructs with microchannels without perfusion was 56.14% and in constructs with perfusion through the microchannels via the bioreactor was 84.13% (**Figure 3D**).

4. Discussion

Physiologically-relevant *in vitro* tumor surrogates require ECM volumes that accommodate an appropriate 3D morphology of embedded cells. The volume of the hundreds to thousands of cells required for breast cancer surrogates may exceed the diffusion limit of oxygen and nutrients ($\leq 100\text{-}200\ \mu\text{m}$). Thus, through-channels and perfusion of the ECM hydrogel are necessary for cell viability and proliferation of larger cell volumes. Additional requirements include structural support of the viscous ECM hydrogel, system transparency for microscopic visualization, and the ability to control media flow. Therefore, as a step in the development of a physiologically-relevant, multi-cellular breast cancer surrogate, the current study employed a thick ($>500\ \mu\text{m}$) 3D construct composed of breast carcinoma cells and breast fibroblasts embedded in an ECM hydrogel, a structural support, and microchannels that were fabricated within a flow-perfusion bioreactor system. To our knowledge, the combination of supporting carbon foam and a collagen/Matrigel ECM hydrogel with multiple microchannels for perfusion is novel.

The ECM found in a breast carcinoma consists of a heterogeneous population of proteins that provide both structural support and functional cues to the surrounding cells. The composition of the ECM as well as the concentration of ECM components are altered in breast cancer in comparison to the normal breast due to the desmoplastic stromal response associated with most breast cancers (Lochter and Bissell, 1995). In addition, the ECM composition varies among different breast cancers, yet there are many commonalities. These include collagen type I, which is the major ECM component of most breast carcinomas (Egeblad *et al.*, 2010), and type IV, laminin, entactin and heparin sulfate proteoglycans that make up the basement membrane (Coopman *et al.*, 1991). These

components are all found to be increased in breast cancer stroma and may play a role in metastatic potential (Naba *et al.*, 2014). To provide a physiologically relevant ECM, our construct included a mixture of bovine collagen I and growth factor reduced Matrigel, which contains many of the other ECM components increased in cancer, including those mentioned above (Kleinman and Martin, 2005).

The ECM hydrogels were supported by carbon foam to minimize hydrogel contraction and maintain microchannel patency. The large volume of ECM hydrogel necessitated an inert structural support, particularly since the ECM hydrogel would not support its own weight. This novel feature of our system was demonstrated to primarily contain carbon on its surface, suggesting an inert surface that would not induce cell toxicity. While no published data on carbon foam cytotoxicity towards epithelial cells exists, breast cancer epithelial cell and breast fibroblast viability was maintained in 3D constructs with the carbon foam, supporting the inert nature of the carbon. Other researchers have corroborated this conclusion when they showed little to no cell toxicity *in vitro* and no foreign body reaction *in vivo* to carbon (Pec *et al.*, 2010).

ECM hydrogel perfusion required that flow be confined to the microchannels with a watertight seal between the ECM hydrogel and support structures (carbon foam and PDMS flow chambers) for monitoring of accurate flow rates. Flow rates resulted in a low Reynold's number, which predicts laminar flow through each microchannel. Contact angle and separation force measurements confirmed that surface treatment of carbon and PDMS resulted in hydrophilicity, which indicated wetting and adherence of the ECM hydrogel. While the mean hydrogel-PDMS contact angle of $80 \pm 9^\circ$ was less than the cut-off for hydrophilicity ($\theta = 90^\circ$), the advancing contact angle of $96 \pm 5^\circ$ was above the cut-off

suggesting that a stronger surface treatment may be necessary to ensure a tight seal between the PDMS and ECM hydrogel. Separation force measurements confirmed adhesion dominated cohesion forces thus indirectly indicating a seal between the PDMS and ECM hydrogel.

Perfusion required open, parallel microchannels to enable nutrient diffusion throughout the entire 3D volume. Experimental analysis showed that microchannels maintained patency during static conditions with no statistically significant change in diameter for up to 161 hours when microchannels were supported by carbon foam and formed by glutaraldehyde-coated rods. Unsupported microchannels (i.e., no carbon foam) and supported microchannels without a glutaraldehyde-coating on the microchannel-forming rods showed a rapid decrease in diameter and complete closure between 38 and 161 hours. The relatively quick closure of microchannels when glutaraldehyde was not employed may be due to the lack of collagen crosslinking along the microchannel wall. These results suggest that a combination of carbon foam support and glutaraldehyde coating on the microchannel-forming rods is necessary to slow ECM hydrogel contraction and maintain microchannel patency.

After characterization of the non-cellular materials in the 3D constructs, breast cancer cells and breast fibroblasts were incorporated to determine if viability could be maintained in the flow-perfusion bioreactor system. It was found that when 3D constructs were perforated with microchannels and perfused with media, viability was increased when compared to solid cell/ECM preparations. These results indicate the importance of the microchannels and media perfusion in maintaining the viability of *in vitro* breast cancer

surrogates. The increased viability is likely due to an increase of nutrients and oxygen available to the embedded cells via the perfused medium.

The flow-perfusion bioreactor and 3D construct system that has been described here incorporates various features, some of which are unique, that will facilitate the tissue engineering of more physiologically relevant *in vitro* 3D breast cancer surrogates. The 3D construct has an enhanced volume compared to lab-on-a-chip systems, which will enable the engineering of larger tumor volumes with different cell types arranged in an appropriate architecture, providing cross-talk between multiple cell types. Incorporation of the ECM hydrogel further increases the physiologic relevance of the system compared to traditional 2D cell culture. The presence of the microchannels allows for perfusion of the construct and enhanced cell viability and also serves as a platform for the engineering of a microvasculature complete with endothelial cells and “neoangiogenesis”, which is vital to cancer development and progression (Weis and Cheresh, 2011).

5. Conclusions

We have fabricated a novel flow-perfusion bioreactor with 3D construct system that provides a platform for tissue engineering of physiologically relevant and architecturally correct *in vitro* breast cancer surrogates. A unique feature of our system is the combination of supporting carbon foam and a collagen/Matrigel ECM hydrogel with multiple microchannels for perfusion to allow for long term cell viability *in vitro*. We showed that the addition of inert carbon foam enabled the fabrication of thicker 3D constructs and microchannels that maintained their integrity over time. We further demonstrated that the ECM hydrogel was adherent to the carbon foam and the PDMS flow chamber for a tight

seal. When human breast carcinoma and stromal cells were embedded in the construct, it was shown that the microchannels with convective flow provided enhanced cell viability.

Acknowledgements

The authors would like to acknowledge: T. Wick, J. Murphy-Ullrich, and P. Schexnailder for their guidance and insightful questions, C. Lawson for her technical assistance, Southern Research for use of their equipment and expertise, the UAB Center for Metabolic Bone Diseases Core Facility for histologic specimen preparation, and the UAB Scanning Electron Microscopy Core Facility for SEM. This work was financially supported by the UAB Comprehensive Cancer Center and the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) grant BC121367.

Disclosure Statement

No competing financial interests exist.

Ethics Statement

No animal or human subjects were used in this study and no institutional ethical approval was required.

References

- Astashkina A, Mann B, Grainger DW. 2012; A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. *Pharmacol Ther*, **134**(1): 82-106.
- Barrila J, Radtke AL, Crabbe A, *et al.* 2010; Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions. *Nat Rev Microbiol*, **8**(11): 791-801.
- Buchanan CF, Voigt EE, Szot CS, *et al.* 2014; Three-dimensional microfluidic collagen hydrogels for investigating flow-mediated tumor-endothelial signaling and vascular organization. *Tissue Eng Part C Methods*, **20**(1): 64-75.
- Carey SP, Kraning-Rush CM, Williams RM, *et al.* 2012; Biophysical control of invasive tumor cell behavior by extracellular matrix microarchitecture. *Biomaterials*, **33**(16): 4157-4165.
- Chen JH, Agrawal G, Feig B, *et al.* 2007; Triple-negative breast cancer: MRI features in 29 patients. *Ann Oncol*, **18**(12): 2042-2043.
- Coopman PJ, Bracke ME, Lissitzky JC, *et al.* 1991; Influence of basement membrane molecules on directional migration of human breast cell lines in vitro. *J Cell Sci*, **98**(Pt 3): 396-401.
- Egeblad M, Rasch M, Weaver VM. 2010; Dynamic interplay between the collagen scaffold and tumor evolution. *Curr Opin Cell Biol*, **22**(5): 697-706.
- Gibot L, Galbraith T, Huot J, *et al.* 2010; A preexisting microvascular network benefits in vivo revascularization of a microvascularized tissue-engineered skin substitute. *Tissue Eng Part A*, **16**(10): 3199-3206.

- Gupta PB, Kuperwasser C. 2004; Disease models of breast cancer. *Drug Discov Today Dis Models*, **1**(1): 9-16.
- Haycock JW. 2011; 3D cell culture: a review of current approaches and techniques. *Methods Mol Biol*, **695**: 1-15.
- Hennings L, Kaufmann Y, Griffin R, *et al.* 2009; Dead or alive? Autofluorescence distinguishes heat-fixed from viable cells. *Int J Hyperthermia*, **25**(5): 355-363.
- Hielscher AC, Gerecht S. 2012; Engineering approaches for investigating tumor angiogenesis: exploiting the role of the extracellular matrix. *Cancer Res*, **72**(23): 6089-6096.
- Kim SS, Utsunomiya H, Koski JA, *et al.* 1998; Survival and Function of Hepatocytes on a Novel Three-Dimensional Synthetic Biodegradable Polymer Scaffold With an Intrinsic Network of Channels. *Ann Surg*, **228**(1): 8-13.
- Kleinman HK, Martin GR. 2005; Matrigel: basement membrane matrix with biological activity. *Semin Cancer Biol*, **15**(5): 378-386.
- Li Q, Chow AB, Mattingly RR. 2010; Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors. *J Pharmacol Exp Ther*, **332**(3): 821-828.
- Lochter AB, Bissell MJ. 1995; Involvement of extracellular matrix constituents in breast cancer. *Semin Cancer Biol*, **6**(3): 165-173.
- Maguire T, Novik E, Chao P, *et al.* 2009; Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates. *Curr Drug Metab*, **10**(10): 1192-1199.

- Naba A, Clauser KR, Lamar JM, *et al.* 2014; Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. *Elife*, **3**: e01308.
- Park JH, Chung BG, Lee WG, *et al.* 2010; Microporous cell-laden hydrogels for engineered tissue constructs. *Biotechnol Bioeng*, **106**(1): 138-148.
- Pec MK, Reyes R, Sanchez E, *et al.* 2010; Reticulated vitreous carbon: A useful material for cell adhesion and tissue invasion. *Eur Cell Mater*, **20**: 282-294.
- Petersen OW, Nielsen HL, Gudjonsson T, *et al.* 2003; Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. *Am J Pathol*, **162**(2): 391-402.
- Rouwkema J, Rivron NC, van Blitterswijk CA. 2008; Vascularization in tissue engineering. *Trends Biotechnol*, **26**(8): 434-441.
- Sadlonova A, Novak Z, Johnson MR, *et al.* 2005; Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. *Breast Cancer Res*, **7**(1): R46-59.
- Schanz J, Pusch J, Hansmann J, *et al.* 2010; Vascularized human tissue models: A new approach for the refinement of biomedical research. *J Biotechnol*, **148**(1): 56-63.
- Sharma SV, Haber DA, Sittman J. 2010; Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. *Nat Rev Cancer*, **10**(4): 241-253.
- Shaw KRM, Wrobel CN, Brugge JS. 2004; Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. *J Mammary Gland Biol Neoplasia*, **9**(4): 297-310.

- Sukmana I. 2012; Microvascular guidance: a challenge to support the development of vascularised tissue engineering construct. *ScientificWorldJournal*, **2012**: 201352.
- Weigelt BBissell MJ. 2008; Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. *Semin Cancer Biol*, **18**(5): 311-321.
- Weis SMCheresh DA. 2011; Tumor angiogenesis: molecular pathways and therapeutic targets. *Nature Medicine*, **17**(11): 1359-1370.
- Wickham MG, Cleveland PH, Binder PS, *et al.* 1983; Growth of cultured corneal endothelial cells onto a vitreous carbon matrix. *Ophthalmic Res*, **15**(2): 116-120.
- Yuan YLee TR. 2013; 'Contact Angle and Wetting Properties' in, *Surface Science Techniques*, eds. G BraccoB Holst (Eds.), Springer Series in Surface Sciences, Verlag Berlin Heidelberg; 3-34.
- Zheng Y, Chen J, Craven M, *et al.* 2012; In vitro microvessels for the study of angiogenesis and thrombosis. *Proc Natl Acad Sci U S A*, **109**(24): 9342-9347.

Table 1. The effect of surface treatment on advancing (θ_{adv}), mean (θ), and receding (θ_{rec})

contact angles reported as mean \pm standard deviation ($n = 3+$).

| | No Coating [$^{\circ}$] | | | 50 v/v% Glutaraldehyde [$^{\circ}$] | | | 63 wt% Nitric Acid [$^{\circ}$] | | |
|--------|---------------------------|-------------|----------------|--|-------------|----------------|--------------------------------------|-------------|----------------|
| | θ_{adv} | θ | θ_{rec} | θ_{adv} | θ | θ_{rec} | θ_{adv} | θ | θ_{rec} |
| PDMS | 116 \pm 8 | 109 \pm 7 | 102 \pm 2 | 107 \pm 0 | 103 \pm 3 | 100 \pm 1 | 96 \pm 5 | 80 \pm 9 | 74 \pm 7 |
| Carbon | 125 \pm 7 | 116 \pm 8 | 109 \pm 9 | 45 \pm 8 | 28 \pm 7 | 23 \pm 3 | 122 \pm 2 | 116 \pm 5 | 107 \pm 3 |

Table 2. For a single microchannel of two different sizes that perforated the 3D constructs, the minimum and maximum volumetric flow rates and Reynold's number are reported.



| Diameter, d [μm] | Flow Rate, q [$\mu\text{l}/\text{min}$] | Reynold's number, Re |
|----------------------------------|--|-------------------------|
| 250 | 11.1 | 0.26 |
| | 307.2 | 7.22 |
| 400 | 11.1 | 0.16 |
| | 947.6 | 13.89 |


Figure 1. The cancer construct is supported and maintained by carbon foam, microchannels, and a perfusion-flow bioreactor. A) Backscatter scanning electron microscopy image of the carbon foam shows gray carbon struts with white oxygen deposits; scale bar = 500 μ m. B) Close up of microchannel-forming rods penetrating through the 3D construct composed of a carbon foam and ECM hydrogel; scale bar = 500 μ m. C) Perfusion-flow bioreactor with 3D construct is housed inside a PDMS flow chamber (transparent sleeve). The direction and flow of working fluid is indicated by arrows.





Figure 2. The effect of carbon foam structural support and rod coating on microchannel diameter. Comparison of microchannel diameter in ECM hydrogel alone (hydrogel), carbon-support ECM hydrogel without glutaraldehyde-coated rods (CF NG), and carbon-support ECM hydrogel with glutaraldehyde-coated rods (CF GS) over 161 hours post microchannel formation.

Figure 3. Cell viability is increased in the constructs in the bioreactor system compared to solid preparations. (A) Autofluorescence intensity cut off determination using dead cells only, a 50%:50% mix of dead and live cells, and live cells only. The black bars indicate the mean and standard deviation of the autofluorescence intensity for each condition. The red vertical line delineates the cut off with maximum sensitivity and specificity used to determine viability. (B) Representative images of autofluorescence in histologic sections from a solid cell/ECM preparation and a microchannel embedded construct with convective flow after 7 days. (C&D) Cell viability as determined by autofluorescence intensity of solid

preparations after 1, 3 and 7 days of culture (C) and comparing solid preparations and microchannel-embedded constructs with and without flow after 7 days (D) (n=3-4 cultures per condition, *denotes $p=0.022$ and ** denotes $p<0.002$, ANOVA).







**THREE-DIMENSIONAL, PREVASCULARIZED, ENGINEERED TISSUE
CONSTRUCTS, METHODS OF MAKING AND METHODS OF USING
THE TISSUE CONSTRUCTS**

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. provisional application entitled, "PREVASCULARIZED 3D CO-CULTURED MODEL FOR BREAST CANCER DRUG DEVELOPMENT," having serial number 61/607,397 filed on March 6, 2012, which is entirely incorporated herein by reference.

BACKGROUND

Current drug development platforms such as two-dimensional (2D) *in vitro* cell culture systems and *in vivo* animal studies do not accurately predict human *in vivo* effectiveness of candidate therapeutics. These cell culture systems have limited similarities to primary human cells and tissues as only one cell type is employed, and animal studies have a generally limited ability to recapitulate human drug response as different species have differences in metabolism, physiology, and behavior. Many experimental drugs fail in clinical studies due to the inability of current screening technologies, such as *in vitro* laboratory tissue analysis and animal studies, to accurately predict how the drugs will behave in people.

Therefore, the drug discovery and development fields need an *in vitro* platform to test candidate therapeutics for better predictions of human response. Current *in vitro* systems (e.g., rotating bioreactors, suspension of spheroids, and growth on a porous scaffold) are limited in size (1-2 mm) and tend to be two dimensional. Attempts at 3D tissue constructs have had only limited success and have been very small or had a short life-span. The failure of these tissue models are due, at least in part, to the absence of a model vascular system to allow diffusion of oxygen and nutrients into the tissue to support more substantial, natural, sustained, tissue growth.

SUMMARY

Embodiments of the present disclosure provide for three-dimensional (3D) prevascularized engineered tissue constructs, 3D prevascularized engineered tissue models for cancer, perfusion bioreactors including the tissue constructs, methods of making the tissue constructs, methods of using the tissue constructs, methods of drug discovery using the tissue constructs, and the like.

An embodiment of a three-dimensional (3D), engineered, vascularized tissue construct of the present disclosure includes a 3D, biocompatible scaffold material; a 3D network of living cells within the scaffold material; a plurality of microchannels extending through the construct, such that a substantial portion of the channels have an inlet at one surface of the construct and an outlet at an opposing surface of the construct, and where the channels form a lumen for allowing passage of liquid through the construct; and a plurality of endothelial cells at least partially lining the lumen.

The present disclosure also provides embodiments of a 3D vascularized biocompatible scaffold for supporting *in vitro*, 3D tissue culture including a 3D, biocompatible scaffold material comprising a solid, porous material, a gel matrix material, or a combination of these materials. The solid, porous material is chosen from the group of materials including: aerogels, reticulate vitreous carbon, particle stabilized foam, and combinations of these materials, and the gel matrix material is chosen from the group of gel matrix materials including: synthetic hydrogels, naturally-derived hydrogels, and combinations of these materials. The 3D vascularized biocompatible scaffold also includes a plurality of channels extending through the scaffold, such that a substantial portion of the channels have an inlet at one surface of the scaffold and an outlet at an opposing surface of the scaffold, and where the channels form lumen for allowing passage of liquid through the scaffold. In embodiments of the 3D, vascularized, biocompatible scaffold, the gel matrix material includes one or more hydrogels selected from the group of synthetic and naturally derived hydrogels including: collagen, fibrin, Matrigel™, bacterial cellulose, HuBiogel™, alginate, polymer based hydrogels, copolymer based hydrogels, polyethylene glycol (PEG) based hydrogels, elastin, and keratin. Also, in embodiments, the 3D vascularized biocompatible scaffold of the present disclosure includes a porous, material selected

from the group including: aerogels, particle stabilized biocompatible foams, reticulate vitreous carbon (RVC), natural electrospun polymers, synthetic electrospun polymers, and combinations of these materials. In embodiments of the 3D, vascularized tissue constructs and scaffolds of the present disclosure, the microchannels have a diameter of about 200 to about 450 microns. In some embodiments, the microchannels have a diameter of about 250 microns or less.

Embodiments of the present disclosure also include three-dimensional (3D), *in vitro*, vascularized cancer models including a 3D tissue construct of the present disclosure. In embodiments the 3D tissue construct of the cancer model includes a biocompatible scaffold material; a 3D network of living cells within the scaffold material, where the network of cells includes cancer cells or a combination of cancer cells and non-cancerous cells; a plurality of channels extending through the construct, such that a substantial portion of the channels have an inlet at one surface of the construct and an outlet at an opposing surface of the construct, where the channels form a lumen for allowing passage of fluid media through the construct; and a plurality of endothelial cells at least partially lining the lumen. In embodiments of the 3D vascularized cancer model of the present disclosure, the model is a human breast cancer model and the network of living cells includes human breast cancer tumor cells and non-cancerous human breast fibroblast cells.

The present disclosure also includes perfusion bioreactors including the 3D engineered tissue constructs of the present disclosure. In an embodiment, perfusion bioreactors of the present disclosure include a three-dimensional (3D), engineered tissue construct of the present disclosure as described above and a tissue chamber configured to house the tissue construct such that the tissue construct forms a barrier between upstream and downstream flow of media through the chamber, directing flow of media through the channels of the tissue construct. In embodiments, the chamber has at least one input portal upstream of the location of the tissue construct, at least one output portal downstream of the location of the tissue construct, and at least one pump to control flow of media through the tissue chamber. As described above, in embodiments, the 3D engineered tissue constructs for use in the bioreactor include a 3D, biocompatible scaffold material; a 3D network of living cells within the scaffold

material; a plurality of channels extending through the construct, such that a substantial portion of the channels have an inlet at one surface of the construct and an outlet at an opposing surface of the construct, where the channels form lumen for allowing passage of fluid media through the construct; and a plurality of endothelial cells at least partially lining the lumen.

The present disclosure also provides methods of making a three-dimensional (3D), vascularized, tissue construct *in vitro*. In embodiments, methods of making the 3D vascularized tissue construct include providing a 3D vascularized biocompatible scaffold, where the scaffold includes a 3D, biocompatible scaffold material and a plurality of channels extending through the scaffold, such that a substantial portion of the channels have an inlet at one surface of the scaffold and an outlet at an opposing surface of the scaffold, forming lumen for allowing passage of liquid through the scaffold. The methods also include seeding the lumen with endothelial cells, such that endothelial cells line at least a portion of the lumen and seeding the scaffold with cells of at least one tissue type. The methods further include perfusing the scaffold with cell culture media, and incubating the seeded scaffold, such that a 3D network of cells of the at least one tissue type grows within the scaffold.

Methods of the present disclosure also include methods of making a three-dimensional (3D), vascularized scaffolding material of the present disclosure. In embodiments, such methods include providing a 3D, biocompatible scaffold material and forming a plurality of microchannels in the scaffold material with a microchannel construct, where the channels extend through the scaffold, such that a substantial portion of the channels have an inlet at one surface of the scaffold and an outlet at an opposing surface of the scaffold, forming lumen for allowing passage of liquid through the scaffold.

The present disclosure also includes methods of screening a test compound including providing a three-dimensional (3D), engineered, vascularized tissue construct of the present disclosure, exposing the 3D tissue construct to the test compound; and monitoring any changes in the tissue construct after exposure to the test compound, where the changes are selected from the group including: histological, biochemical, and physiological changes, or a combination thereof. In embodiments, the screening

methods of the present disclosure include methods of screening a potential cancer therapeutic compound. In embodiments, such methods include providing a 3D, engineered, vascularized cancer tissue construct of the present disclosure where the 3D network of living cells within the scaffold material includes cancer cells or a combination of cancer cells and non-cancerous cells, exposing the 3D cancer tissue construct to a test compound; and detecting changes in growth or viability of the cancer cell network after exposure to the test compound, where a decrease in growth or viability of the cancer cells indicates the test compound is a potential breast cancer therapeutic compound. In embodiments such methods also include detecting toxicity of the cancer therapeutic compound as measured by one or more of histological, biochemical, physiological changes, of the cell network.

The present disclosure also includes bioreactor networks including an array of interconnected bioreactors and at least one pump to control flow of media through the bioreactors, where the bioreactors in the array are in fluid communication with each other. In embodiments of the bioreactor networks, at least one bioreactor in the array contains cells from a different tissue type than the cells in at least one other bioreactor in the array. In embodiments of the bioreactor networks, each bioreactor includes: a three-dimensional (3D), engineered tissue construct of the present disclosure and a tissue chamber configured to house the tissue construct such that the tissue construct forms a barrier between upstream and downstream flow of media through the chamber directing flow of media through the channels of the tissue construct, where the chamber has at least one input portal upstream of the location of the tissue construct and at least one output portal downstream of the location of the tissue construct.

These embodiments, uses of these embodiments, and other uses, features and advantages of the present disclosure, will become more apparent to those of ordinary skill in the relevant art when the following detailed description of the preferred embodiments is read in conjunction with the appended figures.

BRIEF DESCRIPTION OF THE DRAWINGS

Many aspects of the disclosure can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale, emphasis instead being placed upon clearly illustrating the principles of the present disclosure. Moreover, in the drawings, like reference numerals designate corresponding parts throughout the several views.

FIG. 1 is a schematic illustration of an embodiment of a micro-channel construct for forming micro-channels in a 3D construct of the present disclosure.

FIG. 2 is a schematic illustration of an embodiment of a bioreactor of the present disclosure including an embodiment of a 3D vascularized tissue construct of the disclosure with HuBiogel forming at least part of the biocompatible scaffold material. Flow rates can be introduced to expose endothelial cells in the channels to fluid shear stress similar to a physiological environment. Perfusate can be collected downstream and tissue biopsying is possible through a biopsy port.

FIGS. 3A-3B3 illustrate an embodiment of a single bioreactor of the present disclosure including a 3D vascularized tissue construct of the present disclosure. In the embodiment illustrated, the 3D construct has an array of microchannels for enhanced perfusion of the cell-seeded construct. FIG. 3A shows an exploded view of the bioreactor, while FIG. 3B shows a view of the assembled bioreactor.

FIGS. 4A-4B are digital images representing an embodiment of a bioreactor of the present disclosure. FIG. 4A shows a side view of an assembled bioreactor, and FIG. 4B shows a top view of an open bioreactor.

FIG. 5 illustrates a digital image of embodiments of microchannels in 3D tissue constructs of the present disclosure at 500X magnification. FIG. 5 shows an image of a 250 micron diameter channel within an embodiment of a construct of the present disclosure with bacterial cellulose as the scaffold material. Scale bar is 30 microns.

FIG. 6 is an EM image taken at 10X magnification of commercially available reticulate vitreous carbon (RVC) showing the lattice-like structural framework provided by the open pore network. Scale bar is 4mm.

FIG. 7 is a phase contrast microscopy (PCM) image at 40X magnification illustrating MDA-MB-231 cells grown on particle stabilized foam at day 7.

FIG. 8 is a PCM image of MDA-MB-231 cells grown on RVC 45 pores per inch (ppi) at day 7. 3D cell clumps can be seen developing around the material, as compared to (2D) planar cells in the background. Scale bar is 400 microns.

FIG. 9 is a PCM image of MDA-MB-231 tumor cells grown on RVC 45 pores per inch (ppi) at day 11. Cell adhesion is visible on the inside of individual pores of the scaffolding material. Scale bar is 400 microns.

FIG. 10 is an image of MDA-MB-231 tumor cells grown on RVC 45 pores per inch (ppi) at day 16. Scale bar is 400 microns.

FIG. 11 is an image of a 2D control of MDA-MB-231 tumor cells grown on a planar substrate as opposed to a 3D scaffold material at day 16. Scale bar is 400 microns.

FIG. 12 is an image of MDA-MB-231 tumor cells grown on RVC 65 pores per inch (ppi) at day 17. Scale bar is 400 microns.

FIGS. 13A-13B are images of MDA-MB-231 cells grown on different scaffolding materials of the present disclosure. Scale bars are 200 microns. FIG. 13A shows cells at day 11 grown on an aerogel substrate (such as described below in Example 3). Cell adhesion is visible on the inside of individual pores of the scaffolding material. FIG. 13B shows MDA-MB-231 cells grown on RVC 65 at day 11.

FIGS. 14A-14D are images of embodiments of vascularized scaffolding constructs of the present disclosure. FIG. 14A shows an image of a 45 ppi collagen/RVC scaffold (1.5 mg/ml collagen/RVC) with two 400 micron diameter micro-channels shown penetrating through the 4mm thick RVC/collagen scaffold. FIG. 14B shows an image of a 45 ppi collagen/Matrigel/RVC scaffold (1.9 mg/ml collagen/Matrigel/RVC) with three 400 micron diameter micro-channels through the scaffold. FIG. 14C is an image of a section (100um) through a collagen/RVC/Matrigel scaffold material; the microchannels are visible as clear areas, and portions of the RVC scaffolding material are visible as the black portions. FIG. 14D is an image of a section (20um) through gel material illustrating endothelial cells lining the lumen of the microchannels.

FIG. 15 A is a schematic illustration of the scaffold for an embodiment of a disk shaped scaffolding of the present disclosure for an embodiment of a bioreactor of the present disclosure measuring 10 mm diameter x 3 mm height (e.g., version 1 bioreactor in Example 4). FIG. 15B is a schematic illustration of an embodiment of a rectangular-shaped scaffold for another embodiment of a bioreactor of the present disclosure measuring 10 mm width x 5 mm length x 2.4 mm height. (e.g., version 2 bioreactor in Example 4).

FIG. 16 is a digital image of an embodiment of a bioreactor of the present disclosure designed for a rectangular embodiment of a tissue construct of the present disclosure.

DETAILED DESCRIPTION

Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit (unless the context clearly dictates otherwise), between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.

All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be independently confirmed.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.

Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of chemistry, organic chemistry, organometallic chemistry, polymer chemistry, microbiology, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to perform the methods and use the compositions and compounds disclosed and claimed herein. Efforts have been made to ensure accuracy with respect to numbers (*e.g.*, amounts, temperature, *etc.*), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C, and pressure is at or near atmospheric. Standard temperature and pressure are defined as 20 °C and 1 atmosphere.

Before the embodiments of the present disclosure are described in detail, it is to be understood that, unless otherwise indicated, the present disclosure is not limited to particular materials, reagents, reaction materials, manufacturing processes, or the like, as such can vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting.

It is also possible in the present disclosure that steps can be executed in different sequence where this is logically possible.

It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a support” includes a plurality of supports. In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings unless a contrary intention is apparent.

Definitions

In describing and claiming the disclosed subject matter, the following terminology will be used in accordance with the definitions set forth below.

As used herein, the term “engineered” indicates that the engineered object is created and/or altered by man. An engineered object may include naturally derived substances, but the object itself is altered in some way by human intervention and design.

The term “vascularized” as used herein, indicates that an object includes conduits (e.g., vessels, channels, tubes) capable of transporting fluids (e.g., culture media, cells in liquid media, nutrients, etc.) through the object/construct.

As used herein the term “channels” or “microchannels” refers to tube-like formations within a construct. The channels have a generally cylindrical shape, with a generally circular cross-section. The channels have an open (e.g., hollow or substantially hollow) interior (referred to herein as a “lumen”) creating a via/conduit for the transport of fluids. Microchannels, as used herein, have a diameter in the micron range (e.g., 100-900 microns, 200-500 microns, etc.).

As used herein the term “biocompatible” refers to the ability to co-exist with a living biological substance and/or biological system (e.g., a cell, cellular components, living tissue, organ, etc.) without exerting undue stress, toxicity, or adverse effects on the biological substance or system.

The term “biocompatible scaffold material” refers to any compound substance with sufficient structural stability to provide a substrate to support the growth of a living

biological substance (e.g., living cells). In embodiments of the present disclosure the biocompatible scaffold material has a three-dimensional structure (rather than a planar, 2-dimensional structure) to support three-dimensional growth of living cells.

The term “gel matrix material” refers to several different types of semi-solid to solid materials with a gel-like consistency and a structure capable of supporting the growth of living biological substances (e.g., living cells). Both synthetic and naturally derived gel matrix materials exist and are in use by those of skill in the art. Gel matrix materials include hydrogels, such as biocompatible naturally derived or synthetic hydrogels, such as, but not limited to polymer based hydrogels, PEG based hydrogels, cellulose, keratin, elastin, collagen, and the like. Gel matrix materials also include biocompatible polymer or copolymer based gel materials, such a polymer and copolymer based hydrogels. Gel matrix materials may also include a gelling agent or crosslinking agent (e.g., formaldehyde, glutaraldehyde, etc.) to increase the structural stability of the gel (e.g., to give it more “solid” characteristics).

As used herein, the phrase “solid, porous materials” refers to a scaffolding material that has a solid (rather than gel-like) consistency and has an open or porous structure in order to provide a structural framework for supporting the growth of 3D networks of living cells that has a more rigid support than a gel matrix material such as a hydrogel. In embodiments, these solid, porous materials for use in the scaffolding materials and constructs of the present disclosure are inert materials that do not interfere or exert adverse effects on biological materials grown within/on their framework. In embodiments, the solid, porous materials of the present disclosure can have a lattice-like structure that provides ample surface area to support three-dimensional cell growth. Examples of solid, porous materials that can be included in embodiments of the present disclosure are described in the discussion below.

The term “networks of cells” refers to a grouping of a plurality of cells (e.g., three or more) that are connected to each other or otherwise in cellular communication with each other. The term “3D network of cells” includes a network of cells as described above where the cells occupy three dimensional space. In other words, the three or more cells are grouped together in more than one plane.

The term “cancer”, as used herein, shall be given its ordinary meaning, as a general term for diseases in which abnormal cells divide without control and form cancer or neoplastic cells or tissues. The term cancer can include cancer cells and/or precancerous cells. In particular, and in the context of the embodiments of the present disclosure, cancer refers to angiogenesis-related cancer. Cancer cells can invade nearby tissues and can spread through the bloodstream and lymphatic system to other parts of the body. There are several main types of cancer, for example, carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs. Sarcoma is cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is cancer that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the bloodstream. Lymphoma is cancer that begins in the cells of the immune system.

When normal cells lose their ability to behave as a specified, controlled and coordinated unit, a tumor may be formed. Generally, a solid tumor is an abnormal mass of tissue that usually does not contain cysts or liquid areas (although some brain tumors do have cysts and central necrotic areas filled with liquid). A single tumor may even have different populations of cells within it, with differing processes that have gone awry. Solid tumors may be benign (not cancerous), or malignant (cancerous). Different types of solid tumors are named for the type of cells that form them. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) generally do not form solid tumors.

Representative cancers include, but are not limited to, bladder cancer, breast cancer, colorectal cancer, endometrial cancer, head and neck cancer, leukemia, lung cancer, lymphoma, melanoma, non-small-cell lung cancer, ovarian cancer, prostate cancer, testicular cancer, uterine cancer, cervical cancer, thyroid cancer, gastric cancer, brain stem glioma, cerebellar astrocytoma, cerebral astrocytoma, glioblastoma, ependymoma, Ewing's sarcoma family of tumors, germ cell tumor, extracranial cancer, Hodgkin's disease, leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, liver cancer, medulloblastoma, neuroblastoma, brain tumors generally, non-Hodgkin's lymphoma, osteosarcoma, malignant fibrous histiocytoma of bone, retinoblastoma, rhabdomyosarcoma, soft tissue sarcomas generally, supratentorial primitive neuroectodermal and pineal tumors, visual pathway and hypothalamic glioma, Wilms' tumor, acute lymphocytic leukemia, adult acute myeloid leukemia,

adult non-Hodgkin's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, esophageal cancer, hairy cell leukemia, kidney cancer, multiple myeloma, oral cancer, pancreatic cancer, primary central nervous system lymphoma, skin cancer, small-cell lung cancer, among others.

A tumor can be classified as malignant or benign. In both cases, there is an abnormal aggregation and proliferation of cells. In the case of a malignant tumor, these cells behave more aggressively, acquiring properties of increased invasiveness. Ultimately, the tumor cells may even gain the ability to break away from the microscopic environment in which they originated, spread to another area of the body (with a very different environment, not normally conducive to their growth), and continue their rapid growth and division in this new location. This is called metastasis. Once malignant cells have metastasized, achieving a cure is more difficult.

Benign tumors have less of a tendency to invade and are less likely to metastasize. Brain tumors spread extensively within the brain but do not usually metastasize outside the brain. Gliomas are very invasive inside the brain, even crossing hemispheres. They do divide in an uncontrolled manner, though. Depending on their location, they can be just as life threatening as malignant lesions. An example of this would be a benign tumor in the brain, which can grow and occupy space within the skull, leading to increased pressure on the brain.

It should be noted that precancerous cells, cancer, tumors are often used interchangeably in the disclosure.

The term "polymer" includes any compound that is made up of two or more monomeric units covalently bonded to each other, where the monomeric units may be the same or different, such that the polymer may be a homopolymer or a heteropolymer. Representative polymers include polyamides, such as polypeptides, poly-*N*-substituted glycines (polypeptoids), polysaccharides, polyethylene glycol or polyethylene oxide, plastics (e.g., poly-L-lactic acid, poly-L-glutamic acid and co-polymers thereof), nucleic acids and the like, where the polymers may be naturally occurring, non-naturally occurring, or synthetic. The term "bio-polymer" refers to a polymer made of biologically-derived and/or biologically compatible compounds

The term "attached" or the phrases "interacts with" and "associated with" refers to a stable physical, biological, biochemical, and/or chemical association. In general,

association can be chemical bonding (e.g., covalently or ionically), a biological interaction, a biochemical interaction, and in some instances a physical interaction. The association can be a covalent bond, a non-covalent bond, an ionic bond, a metal ion chelation interaction, as well as moieties being linked through interactions such as, but not limited to, hydrophobic interactions, hydrophilic interactions such as hydrogel bonding, charge-charge interactions, π -stacking interactions, combinations thereof, and like interactions.

Discussion

The present disclosure provides three-dimensional (3D), engineered, vascularized tissue constructs, bioreactors including the constructs, methods of making the constructs, and various methods of employing the constructs for tissue design, drug discovery, and many other uses. The 3D engineered, vascularized tissue constructs of the present disclosure represent custom-built, microphysiological platforms that support long-term tissue growth, recapitulate physiological tissue function, provide a model of human disease progression or response to external challenge (drug or pathogen), among other advantages over current technologies.

Current drug discovery platforms use 2D cell culture systems to replicate the tissue microenvironment and physiologic endpoints. 3D tissue models using primary human cells better replicate the biochemical and biophysical characteristics of the tissue. In addition, the gene expression profiles of 3D cultures more accurately mimic the native tissues and more accurately reproduce drug sensitivity responses as compared to 2D culture. At present, many 3D tissue models are developed using synthetic (hydrogel, alginate) or animal-derived (Matrigel™, HuBiogel™, collagen) biomatrix scaffolds. Furthermore, most 3D tissue construct approaches typically only culture the primary parenchymal cell type without incorporating stromal or vascular components. In contrast, the 3D vascularized tissue constructs of the present disclosure represent more 'fully human' tissue constructs by employing a biomatrix scaffold suitable for long-term culture of the appropriate human primary cell types with

parenchymal and stromal cellular components in a vascularized network to accurately mimic tissue function and response to drugs.

A network of microchannels engineered within the tissue constructs of the present disclosure provides vascularization to the construct to overcome oxygen diffusion limitations in larger tissues and allows introduction of cyclic mechanical stimulation for providing proper endothelial function and metabolic communication with surrounding tissue. The vascularization of the tissue construct allows for better three-dimensional growth and growth on a larger scale with longer sustainability. These advances in 3D tissue model technology will accelerate drug development by providing tissue constructs with more physiologically relevant functions and structures and, thereby, more *in vivo*-like metabolic and molecular predictive endpoints.

The 3D, vascularized tissue constructs of the present disclosure are compatible with various cell types, and, thus, can be used to grow tissue constructs including any different cell type that can then be employed for many different uses. For instance, both healthy and diseased cells can be grown in the physiological environment of the present 3D vascularized tissue scaffolds and can be used to mimic various disease states, organ systems, and the like. Also, human cells from donors and patients can be used in the present constructs to create physiologically relevant tissue constructs and accurate representations of disease states. Using patient cells in making a 3d vascularized tissue construct of the present disclosure can provide a platform for personalized medicine, such as by providing a personalized model for *in vitro* testing drug interactions with a patient's own tissue.

These 3D multicellular tissue constructs are cultured in novel microphysiological perfusion bioreactors that permit real-time non-destructive assaying of tissue function and the capacity to connect multiple organ systems (in a 'plug-and-play' design) to replicate complex organism physiology. The bioreactors of the present disclosure are engineered to integrate with sampling and optical imaging technologies to evaluate tissue-specific function and response to drug and toxin challenges. The bioreactors can be incorporated into an array, with each bioreactor supporting a tissue construct. These 'plug-and-play' platforms can be interconnected and reconfigured to include a variety of different tissues. In embodiments the 3D tissue constructs of the present disclosure can

be integrated into an array system with tissue constructs of different tissue types and/or disease states to form an integrated microphysiological system for more predictive, rapid, and cost effective drug discovery, development, efficacy and toxicology testing strategies. These innovative approaches will supplant and/or enhance current approaches utilizing 2D cell cultures and animal testing regimens for drug development and validation which are expensive, have limited predictive capacity and require extensive time for completion. The 3D tissue constructs of the present disclosure and integrated arrays of the tissue constructs will provide powerful new paradigms for more cost effective and timely translation of drugs from bench to bedside.

Embodiments of the 3D vascularized tissue constructs of the present disclosure, disease state models using the tissue constructs, bioreactors for growth and maintenance of the tissue constructs, bioreactor arrays, methods of screening test compounds using the tissue constructs, and methods of making the tissue constructs of the present disclosure and other embodiments of the present disclosure are described in greater detail below.

3D engineered, vascularized tissue constructs

The 3D engineered, vascularized tissue constructs of the present disclosure include a three-dimensional, biocompatible scaffold material for providing structural support for cell growth; a three-dimensional network of living cells within the scaffold material; a plurality of microchannels extending through the construct, where the microchannels are at least partially lined on the inner surface (lumen) with endothelial cells. The present disclosure includes both the 3D vascularized tissue constructs as well as 3D vascularized scaffolds for supporting tissue growth (e.g., pre-seeded scaffolds without the network of living cells).

Biocompatible scaffold material:

In order to support growth of cells in three-dimensional space, the tissue constructs of the present disclosure provide a biocompatible scaffolding material that provides structural support and integrity to the construct. In embodiments the biocompatible scaffolding material is a gel matrix material, a solid porous material, or a combination of both of these materials.

The use of gel matrix materials for use in tissue engineering and lab-on-a-chip designs is well known. In embodiments of the constructs of the present disclosure any such biocompatible gel matrix materials used in these applications can be used to provide the structural scaffolding of the present disclosure. Representative gel matrix materials include, but are not limited to synthetic and naturally-derived hydrogels. The gel matrix material of the present disclosure can include synthetic hydrogels, naturally-derived hydrogels, and combinations of both synthetic and natural hydrogels. Such hydrogels are well known in the art and can be tailored to have various physical properties (e.g., by incorporation of various polymer materials) and can be enhanced with nutrients and other proteins (e.g., growth factors). While not intending to limit the scope of this disclosure, some aspects of hydrogels and representative hydrogels are discussed below.

Generally described, a hydrogel is a natural or synthetic network of polymer chains that are hydrophilic, with water as the dispersion medium. Hydrogels are highly absorbent (they can contain over 99.9% water) and possess a degree of flexibility very similar to natural tissue, due to their significant water content. Hydrogels can be tailored to have material properties that closely match the mechanical properties of natural tissues by controlling and optimizing their porosity and conjugated adhesion and other bio-recognition or gel crosslinking molecules.

In embodiments, hydrogels can be specifically designed via tunable material properties (e.g., gel stiffness, porosity, and degradation rate). Selection of the polypeptides that make up the hydrogel and the degree of cross-linking of the polypeptides (e.g., by addition of various crosslinking agents, gelling agents, and the like) can be used to control the material characteristics of the hydrogel. In addition, the hydrogel can be designed to control the concentration of presented bioactive substrates (e.g., adhesion substrates, protease substrates, and the like). In embodiments, the hydrogel can be a hybrid synthetic material incorporating synthetic polymers such as poly(ethylene glycol) in addition to biosynthetically derived, repetitive proteins. In some embodiments, hydrogels can be formed from protein polymers that can be crosslinked into a hydrogel using a chemical, physical, and/or biological crosslinking agent (e.g., enzymes). In some embodiments, hydrogels have been synthesized that include

specific protein binding domains; thus, enabling binding of proteins useful for cell growth and maintenance, such as growth factors.

The constructs of the present disclosure can include either or both naturally-derived and synthetic hydrogels. In embodiments of the present disclosure, representative naturally-derived hydrogels include, but are not limited to: collagen, fibrin, Matrigel™, bacterial cellulose, HuBiogel™, and combinations thereof.

In embodiments of the 3D vascularized tissue constructs of the present disclosure, the gel matrix material can be naturally derived hydrogels of bacterial cellulose and/or fibrin. Bacterial cellulose and fibrin hydrogels have different chemical compositions, mechanical structures, and can support different cell types. Bacterial cellulose, a non-degradable hydrogel derived from synthesis of cellulose nanofibers by bacteria, has been shown to support vascular smooth muscle cells, endothelial cells, and osteoblasts. Fibrin gel, a degradable product of blood clotting found in mammals, has been shown to support many cell types including breast cancer cells. Fibrin also plays an important role in tissue regeneration and repair. It is the major protein component of blood clots and is made via the cleavage of the protein fibrinogen by the enzyme thrombin. Fibrin can form a gel at physiological temperatures and has been used extensively in biomedical engineering applications, ranging from cardiovascular tissue engineering to wound healing endeavors.

Collagen is another natural hydrogel that can be used in the 3D vascularized tissue constructs of the present disclosure. Collagen is the most abundant protein found in mammals and is the major component of extracellular matrix. Type I collagen is the most abundant of all the collagens and plays an important role in tissue regeneration and repair. It is commercially available as a solubilized material and has been used as a 3D matrix material in many biomedical and tissue engineering applications including orthopedic tissue engineering. Type I collagen forms a hydrogel at physiological temperatures.

Matrigel™ (BD Biosciences), is a solubilized basement membrane matrix extracted from murine tumor 30. This hydrogel is also used in many tissue engineering applications. HuBiogel™ is a hydrogel that is a human biomatrix created by Vivo Biosciences (VBI). HuBiogel is a natural extracellular matrix (ECM) including Col-I,

laminin, Col-IV, Col-III, entactin, and HSPG, but lacks all major known growth factors. It is more compatible with human tissues and safe, being neither angiogenic nor mitogenic. HuBiogel promotes cell growth and differentiation via local growth factor signals and allows long-term culture on or more cell types. It is compatible with human cells and/or for growth of human tissue models.

In embodiments of the present disclosure, representative synthetic hydrogels include, but are not limited to: alginate, polyethylene glycol (PEG) based hydrogels, polymer oligo(polyethylene glycol fumarate) (OPF), other biocompatible polymer or copolymer based hydrogels, and combinations of these materials.

OPF hydrogel is a synthetic polyethylene glycol (PEG) based hydrogel. OPF is a novel hydrogel developed at Rice University and has been used as a 3D matrix for soft tissue and orthopedic tissue engineering applications 36-39. Its properties, such as non-toxicity, biocompatibility and rapid gelling make it a promising material for 3D cell culture. OPF hydrogels, other PEG based hydrogels, alginate, and other synthetic hydrogels can be used as a gel matrix for forming the biocompatible scaffolding material of the present disclosure.

In embodiments of the present disclosure where the biocompatible scaffold material includes a gel matrix material it may also include one or more crosslinking agents, gelling agents, or combinations, where such agents are capable of increasing the structural stability and/or structural integrity of the gel matrix material. Due to the high content of hydrogels, some hydrogels can have a more fluid consistency than desired in the constructs of the present disclosure. Thus, in some embodiments, gelling agents and/or crosslinking agents, or the like may be used to “solidify” or “cure” the hydrogel. In some embodiments, application of heat alone may be sufficient to gel or “cure” the hydrogel. A combination of heat application, use of gelling or crosslinking agents or other fillers may be employed in embodiments of the present disclosure to provide the desired structural integrity of the scaffolding material.

While gel matrix materials, such as hydrogels, have a history of use in tissue engineering and cell culture applications with a well-plate design or thin lab-on-a-chip technologies, they have, in the past, been unable to support the growth of a large 3D tissue construct and/or long-term maintenance. The vascularization of the construct as

provided by the present disclosure overcomes some of these difficulties, allowing additional delivery of culture media, nutrients, and the like to cells to allow for more sustained and substantial tissue growth. In embodiments of the present disclosure gel matrix material alone as the scaffolding material is appropriate for embodiments of constructs for use in well-plate format, some bioreactor designs, and other embodiments. However, for some applications, additional structural integrity may be desired in the scaffolding material.

In embodiments of the 3D vascularized tissue construct of the present disclosure, the biocompatible scaffolding material can include a solid, porous, material such as, but not limited to, aerogels, particle stabilized biocompatible foams, reticulate vitreous carbon (RVC), natural electrospun polymers, synthetic electrospun polymers, and combinations of these materials. Such solid, porous materials provide a solid structural framework for supporting the growth of 3D networks of living cells. In embodiments, these solid, porous materials for use in the scaffolding materials of the constructs of the present disclosure are inert materials that do not interfere or exert adverse effects on biological materials grown within/on their framework.

Some of these solid, porous materials have a lattice-like structure that provides ample surface area to support three-dimensional cell growth. For instance, reticulate vitreous carbon (RVC) has a solid, lattice structure provided by the open pore network. An image of RVC is shown in FIG. 7. Other solid porous materials also provide a lattice-type or web-like structural features, such as aerogels, particle stabilized biocompatible foams, natural and synthetic electrospun polymers, and the like. Aerogels are solid materials derived from gels, where the liquid has been evaporated from the gel to leave an ultra-light, but strong solid framework. These materials and other biocompatible, solid, porous materials can be used alone or in combination with other materials, such as the gel matrix materials discussed above in forming the scaffolding material of the present disclosure.

Thus, in embodiments of the 3D vascularized tissue constructs and 3D vascularized scaffolding materials of the present disclosure, the biocompatible scaffold material can include one or more solid, porous materials and one or more gel matrix materials, as well as any other compounds used to enhance, modify, or control the

properties of the scaffolding material (e.g., binding agents, gelling agents, cross-linking agents, proteins, polymers, and the like). In embodiments of the present disclosure, the biocompatible scaffolding material includes reticulate vitreous carbon and/or an aerogel combined with one or more gel matrix materials, such as, but not limited to, Matrigel™, bacterial cellulose, collagen, fibrin, elastin, keratin, HuBiogel, and combinations thereof. In embodiments of the present disclosure, the biocompatible scaffolding material includes RVC, Matrigel™ and collagen, as well as optional crosslinking and/or gelling agents, such as, but not limited to glutaraldehyde, formaldehyde, and the like.

Vascularization of scaffold:

The 3D engineered vascularized tissue constructs and 3D vascularized scaffolding materials of the present disclosure include a plurality of channels extending through the construct. In embodiments, the channels are microchannels. In embodiments, the microchannels have a diameter of about 1 to about 1000 microns, from about 5 to about 600 microns, or from 200 to about 450 microns, and other ranges within and/or overlapping the stated ranges. In embodiments, the microchannels have a diameter of about 250 microns or less. In embodiments the microchannels have a diameter from about 5 to about 250 microns. The microchannels are configured such that a substantial portion of the channels have an inlet at one surface of the construct and an outlet at an opposing surface of the construct. The microchannels are substantially hollow, such that the channels form lumen for allowing passage of liquid through the construct. Thus, the microchannels create a vascular network within the scaffolding construct to facilitate the delivery of cell culture media, nutrients, oxygen, proteins, growth factors, and the like to various parts of the 3D construct, allowing for improved growth and maintenance of cells growing within the construct. In embodiments, the microchannels are substantially aligned (e.g., they are generally oriented in the same direction to allow for unidirectional flow of fluid/media through the channels).

In embodiments of the 3D vascularized constructs and scaffolding of the present disclosure, the microchannels are at least partially lined on the inner surface (lumen) with endothelial cells. These endothelial cells can form an integrated network to approximate the lining of a physiological vessel. Endothelial cells are introduced to the

channels and cultured so that a plurality of endothelial cells at least partially lines the lumen. The endothelial cells can be introduced in various manners known to those of skill in the art. For instance, in an embodiment, the scaffolds/constructs having microchannels formed within the construct can be placed in culture medium containing endothelial cells and incubated for a sufficient amount of time for endothelial cell growth. In other embodiments, the endothelial cells may be seeded by perfusion with media containing the endothelial cells in a bioreactor, by a syringe pump, by injection into the microchannels or other method of delivering endothelial cells to the microchannels of the construct.

In embodiments of methods of making the constructs and scaffolds of the present disclosure, the microchannels are formed by use of a microchannel construct. In embodiments, the microchannel construct is made of a rigid, durable material, such as a metal (e.g., stainless steel), glass, polymer, resorbable filaments, and the like. The microchannel construct can have a base and an array of rods or wires for forming the microchannels. FIG. 1 represents a schematic illustration of an embodiment of a microchannel construct of the present disclosure. In embodiments of the present disclosure, the rods or wires have a generally cylindrical shape and have a cross section similar to the desired cross section of the microchannels. Thus, the rods/wires can have a diameter of about 10 to about 1000 microns, 100 to about 600 microns, about 200 to about 400 microns, and about 250 microns, and the like. In embodiments, the microchannels can also be formed by laser machining.

The microchannel construct can be used to form the channels in the 3D scaffolding material in various ways. In an embodiment where the scaffolding material includes a gel matrix material, the microchannel construct can be inserted into the gel matrix material or combination solid porous material and gel matrix material before curing (e.g. crosslinking, gelling, otherwise “solidifying”) the gel matrix material. Then the microchannel construct can be removed after the gel has cured, leaving microchannels within the scaffold/construct. In other embodiments, the microchannel construct can be inserted/punched into the gel matrix, solid porous material, or combination solid porous material and gel matrix) after curing, forming or “punching” the channels into the scaffold/construct. Other methods for forming the microchannels in

the construct/scaffolding may also be employed and are considered to be within the scope of the present disclosure.

3D network of cells:

The 3D vascularized tissue constructs of the present disclosure also include a 3D network of cells within the scaffolding material. The network of cells includes a plurality of cells growing in three-dimensional space (e.g., in more than one plane), where the cells are interconnected in some manner, such as physical contact, in cellular communication, etc. The tissue constructs of the present disclosure can support the growth of virtually any kind of cells, with animal cells being of particular interest. In embodiments, the tissue constructs of the present disclosure include mammalian cells, in particular human cells. The cells can be from any tissue of interest, including healthy and/or diseased tissue. The cells can be introduced to the scaffolding material after formation of the scaffolding material and microchannels, or, in some embodiments, contemporaneously with the addition of a gel matrix material or other agents. The cells can be introduced in culture medium, by injection, perfusion, co-incubation, or a combination of these methods and other methods known to those of skill in the art.

The tissue constructs of the present disclosure may include pathologic cells (e.g., for modeling diseased tissue), healthy cells, or a combination of healthy and pathologic cells. In general, the cell type can be a pathogenic cell that causes or is capable of causing a disease such as cancer. In an embodiment, the cell type can include a cancer cell, such as cancer human cells and/or precancerous human cells. In an embodiment, the cancer cells can include cancer cells such as metastatic cancer cells. In an embodiment, the cancer human cells can include human cancer cells such as metastatic human cancer cells. The cell types can correspond to cancers such as those defined above. In particular, the cell types can include prostate cancer cells, breast cancer cells, brain cancer cells, ovarian cancer cells, bladder cancer cell, lung cancer cells, and colon cancer cells, in humans or mammals. Although cancer and cancer cells are referred to herein, the cancer and cancer cells can be replaced with pathogenic cell.

In embodiments, the cells include a combination of cancer cells and healthy (non-cancerous) cells. In this manner, it is possible with the constructs of the present disclosure to model certain disease states in a manner similar to the *in vivo* state of the

disease. For instance, in the case of some tumors, the 3D vascularized tissue constructs of the present disclosure allow formation of a 3D tumor in combination with healthy tissue that mimics the structure and composition of the tumor in a host. The structure provided by the scaffolding material and the vascularization provided by the microchannels allows improved growth of the cells to form tissues with a spatial orientation and structure more similar to the physiologic state.

In some embodiments of the present disclosure, the constructs can be used to provide a three dimensional (3D), *in vitro*, vascularized cancer model. In some such embodiments, the 3D tissue construct includes the biocompatible scaffold material with a three-dimensional network of living cells within the scaffold material, where the network of cells includes cancer cells or a combination of cancer cells and non-cancerous cells. The 3D vascularized cancer model also includes a plurality of channels extending through the construct to form lumen and a plurality of endothelial cells at least partially lining the lumen, as described above.

In embodiments, the 3D vascularized tissue construct of the present disclosure can be used to provide a model of human breast cancer. In embodiments, the 3D vascularized tissue construct includes a network of cells including breast cancer tumor cells and healthy breast tissue cells such as, but not limited to, breast fibroblast cells and/or breast epithelial cells). In some embodiments of the breast cancer model of the present disclosure, the breast cancer tumor cells form a spheroid structure. Spheroids are often formed by breast cancer cells *in vivo* in hosts with breast cancer. Embodiments of the present disclosure also include models of other cancers and other diseases using the 3D vascularized tissue constructs of the present disclosure.

Configurations of 3D vascularized scaffolding and tissue constructs:

In embodiments, the physical properties (e.g., size, shape, density, etc.) of the 3D vascularized tissue construct and/or the 3D biocompatible vascularized scaffolding can be configured and/or adapted for various applications. For instance, the 3D scaffolds/tissue constructs of the present disclosure can be adapted to have different sizes, shapes, thickness, density, and the like for various assay, culture, imaging, and screening applications, as well as other uses and applications. For instance, in some embodiments, the tissue construct is configured to be placed in a well-plate and/or a

flattened parallel plate flow chamber. In other embodiments the tissue construct is configured for placement on a confocal imaging device, a fluorescence imaging device, a phase contrast imaging device, or interchangeably on any of these devices. In embodiments, the tissue construct and/or scaffold of the present disclosure is adapted to be placed in a bioreactor tissue chamber as well as one or more of the other above described devices. For instance, a tissue construct adapted for a well plate format may not need as much structural integrity, so a softer gel matrix scaffolding material may be appropriate. In some embodiments where more structural integrity is desired, a solid porous material, such as RVC, may be included in the scaffolding material. Shape can also be tailored to the appropriate application. For instance, in embodiments for a well plate, a more disk-like structure for the construct may be desired (e.g., FIG. 15A), whereas for use on a confocal imaging device, a more rectangular shape may be appropriate (e.g., FIG. 15B). Also, the shape of the construct may be adapted for use in various bioreactors. For instance, the construct may have a somewhat cylindrical or disk shape (e.g., FIG. 15A) for use in a cylindrical bioreactor, such as shown in FIG. 4A and 4B, while the construct may have a more rectangular shape (e.g., FIG. 15B) for use in a rectangular bioreactor, such as shown in FIG. 16.

As mentioned above, the present disclosure encompasses not only the three dimensional (3D) vascularized tissue constructs of the present disclosure, but also 3D vascularized biocompatible scaffolds for supporting *in vitro*, 3D tissue culture. The 3D vascularized biocompatible scaffolds are similar to the tissue constructs, but do not yet include a 3D network of cells within the scaffold material. Thus, these scaffolds can be used, as described above, to grow 3D networks of cells and to make tissue models and disease models as described above. In embodiments, the 3D, biocompatible scaffold material of the present disclosure can include a solid, porous material, a gel matrix material, or a combination thereof, as described above.

The microchannels of vascularized biocompatible scaffolds may or may not include the layer of endothelial cells within the lumen. Endothelial cells could be added to the scaffolds at a later time, before or contemporaneously with the addition of the cells of interest. The present disclosure also includes kits including a 3D biocompatible scaffold of the present disclosure, including the biocompatible scaffolding material and a

plurality of microchannels as described above, with or without the endothelial cells lining the lumen of the microchannels. In embodiments, the kit can also include a culture of endothelial cells and/or a culture of other tissue cells of interest, and instructions for adding the endothelial cells and/or other tissue cells of interest to produce a 3D vascularized tissue construct of the present disclosure.

Methods of making the tissue constructs and scaffolds

The present disclosure also provides methods of making the 3D vascularized tissue constructs and biocompatible scaffolds of the present disclosure and methods of growing a three-dimensional (3D) tissue construct *in vitro*. In embodiments, methods of making a 3D vascularized scaffold of the present disclosure includes providing a three dimensional (3D) vascularized biocompatible scaffold, where the scaffold includes a 3D, biocompatible scaffold material and a plurality of channels extending through the scaffold, where the channels form lumen for allowing passage of liquid through the scaffold.

In embodiments the method of making the biocompatible scaffold and tissue construct of the present disclosure includes forming the microchannels by using a microchannel construct of the present disclosure, as described above. In some embodiments the microchannels are formed by using the construct to punch channels in the scaffolding material, while in other embodiments, the microchannel construct is inserted into a material for forming the scaffolding material (such as a gel matrix material or a combination of a gel matrix material and solid porous material, and the gel matrix material is cured or gelled around the microchannel construct. Then the construct is removed, leaving channels within the scaffolding material. In embodiments, the method further includes seeding the lumen with endothelial cells, such that endothelial cells line at least a portion of the lumen. Embodiments of making a 3D vascularized tissue construct of the present disclosure further include seeding the scaffold with cells of at least one tissue type. The scaffold can then be perfused with cell culture media including cells of interest (or otherwise contacted with the cells of interest) to seed the scaffold material with the cells of interest. In embodiments, the seeded scaffold material is incubated and a 3D network of cells of the at least one tissue type grows within the scaffold.

Bioreactors

The 3D vascularized tissue constructs of the present disclosure are also adapted to be included in a bioreactor. Bioreactors for housing the tissue constructs of the present disclosure are also included in the scope of the present disclosure. In embodiments, a bioreactor is provided that has a tissue chamber for housing the tissue construct, and upstream and downstream portals for the transfer of fluids (e.g., culture medium) and an optional pump for controlling the flow of culture fluids. A schematic of an embodiment of a bioreactor of the present disclosure is illustrated in FIG. 2. The bioreactors of the present disclosure can be designed and/or adapted for various embodiments of tissue constructs. For example, bioreactors can be adapted for a disk shaped tissue construct, and in other embodiments, the bioreactor can be adapted for a substantially rectangular shaped tissue construct. In embodiments the bioreactors are also compatible with an imaging device, such as a confocal imaging device, a fluorescence imaging device, a phase contrast imaging device, or interchangeably with any of these devices. In embodiments, the bioreactor is configured to allow imaging of the tissue construct while the tissue construct is within the bioreactor.

An embodiment of a representative bioreactor of the present disclosure is shown in FIG. 3, which will be described in greater detail here as a representative embodiment. The bioreactor (10) includes a tissue chamber (11) for housing a 3D vascularized tissue construct (12) having a plurality of microchannels (13). The bioreactor also includes an input area/chamber (14), and output area/chamber (16) and a cap (18). The input and output chambers include portals (20). The input chamber is upstream of the tissue chamber and includes input portals (22) (such as, but not limited to, an input portal (22A) for introducing fresh media bolus and input portal (22B) for introducing fresh assay reagents). Not all embodiments will include every portal illustrated and described here, in that in some embodiments, some input portals may serve to input various items, while some output portals may also be used for a variety of different outputs. In an embodiment, the bioreactor includes upstream output portals (24). In embodiments an output portal (24A) provides a portal for extracting fluid from the construct for analysis. Another output portal, (24B) can provide access to flush fluid, make a media change and the like. In embodiments, the bioreactor also includes a downstream output portal

(28) for the exit of perfusate from the output chamber (16). The bioreactor of the present disclosure may also include an input (26) for continuous media flow into the input chamber. In embodiments, the bioreactor also includes a biopsy port (30) for extracting a biopsy sample from the tissue construct and an optional o-ring (31) for a seal to other devices or systems, such as another bioreactor. In embodiments of the present disclosure the tissue construct acts as a barrier between the input and output chambers (14 and 16), such that flow of media introduced by a pump, syringe, etc., flows through the microchannels of the construct.

In embodiments of the bioreactor of the present disclosure, the bioreactor includes a three dimensional (3D), engineered tissue construct comprising a three-dimensional, biocompatible scaffold material (as described above); a three-dimensional network of living cells within the scaffold material; and a plurality of channels extending through the construct, such that a substantial portion of the channels have an inlet at one surface of the construct and an outlet at an opposing surface of the construct, and a plurality of endothelial cells at least partially lining the lumen; a tissue chamber configured to house the tissue construct such that the tissue construct forms a barrier between upstream and downstream flow of media through the chamber directing flow of media through the channels of the tissue construct, where the chamber has at least one input portal upstream of the location of the tissue construct and at least one output portal downstream of the location of the tissue construct; and at least one micropump, syringe pump, or peristaltic pump to control flow of media through the tissue chamber.

Bioreactor networks/arrays

As discussed above, the bioreactors of the present disclosure can be adapted to be interconnected to create an array of bioreactors. In the array, different bioreactors can support tissue constructs of different tissue types, such that different tissue types can be interconnected in the array. This allows testing, assaying, observing, analyzing of cellular and other interactions between tissue types. It also allows one to monitor how a proposed therapeutic or other compound exerts an effect on one tissue type and may exert a different effect on another tissue type. This “plug-and-play” design allows one to mix up tissue types and to interconnect tissue types in a configuration more accurately modeling a host system.

In embodiments, a bioreactor network includes an array of interconnected bioreactors according to the present disclosure and at least one pump to control flow of media through the bioreactors, such that the bioreactors in the array are in fluid communication with each other

Methods of screening

The present disclosure also includes methods of screening a test compound using the 3D vascularized tissue constructs of the present disclosure. In embodiments, the tissue constructs can be used as a model of diseased and/or healthy tissue to determine the effect of a candidate drug, therapeutic, biological agent, or other compound on the tissues. In embodiments, the method of screening includes providing a three dimensional (3D), engineered, vascularized tissue construct as described above with a network of living cells of a tissue of interest within the scaffold material, exposing the 3D tissue construct to the test compound; and monitoring any changes in the tissue construct after exposure to the test compound, wherein the changes are selected from the group consisting of histological, biochemical, and physiological changes, or a combination thereof. The constructs can be used to monitor not only the responses of a diseased tissue type to a potential drug candidate but also the responses of healthy tissues to the same compound in order to test for toxicity and/or adverse effects.

In embodiments, the tissue constructs of the present disclosure can be used to screen potential breast cancer therapeutic compounds. The compounds can be screened using a tissue construct mimicking human breast cancer diseases (e.g., including breast cancer cells and/or a combination of breast cancer cells, and other healthy, human breast cells.) In such embodiments, the construct, including the 3D breast cancer tissue and/or other diseased or healthy cells is contacted with a test compound (e.g., a potential breast cancer therapeutic). The method includes detecting changes in growth or viability of the breast cancer cell network and/or healthy breast cells after exposure to the test compound. In embodiments, a decrease in growth or viability of the breast cancer cells indicates the test compound is a potential breast cancer therapeutic compound. The method may also include detecting toxicity of the breast cancer therapeutic compound as measured by histological, biochemical,

physiological changes, or a combination thereof, of the cell network. These methods and variations of these methods can be used to screen a variety of compounds for effects on various tissue types that can be grown in the 3D vascularized tissue constructs of the present disclosure.

EXAMPLES

Now having described the embodiments of the present disclosure, in general, the examples describe some additional embodiments of the present disclosure. While embodiments of present disclosure are described in connection with the examples and the corresponding text and figures, there is no intent to limit embodiments of the present disclosure to this description. On the contrary, the intent is to cover all alternatives, modifications, and equivalents included within the spirit and scope of embodiments of the present disclosure.

Example 1—3D vascularized tissue constructs with gel matrix scaffolds

The present Example describes the creation of 3D engineered tissue models for evaluation of breast cancer drug therapies. It is expected that this platform will dramatically reduce the time and cost associated with regulatory approval of an anti-cancer therapies, currently a multi-billion dollar endeavor. Cell/biomaterial models formed in 3D represent an emerging paradigm in drug development in which novel therapeutic compounds are rapidly developed, repurposed or terminated. However, 3D models with a prefabricated vascular network system, which will supply the cells with oxygen and nutrients to larger volumes, have not been previously explored. The prevascularized 3D engineered tissue construct of the present disclosure mimics human breast cancer, providing a 3D model of the disease that will respond to anti-cancer therapeutic intervention in a manner representative of the *in vivo* human response.

Materials and Methods:

The two scaffolds used were bacterial cellulose and fibrin. Channels were created in each biomaterial through use of a micro channel construct (FIG. 1). The scaffolding materials were prevascularized by forming micro-channels of 250 μm or less in diameter, with the use of a microchannel construct having an array of wires/micro-

rods of approximately 250 microns in diameter. For bacterial cellulose constructs, the microchannel construct was inserted into the scaffolding material, a gel matrix material including bacterial cellulose. After insertion of the micro channel construct, the bacterial cellulose matrix material was cured (e.g., “gelled”).

After gelation of the matrix material to form the scaffolding, the microchannel construct was removed, leaving an array of microchannels through the scaffolding construct. For fibrin gel constructs, the microchannel construct was punched into the gel matrix material of fibrin gel after gelation; removal of the microchannel construct left an array of microchannels through the fibrin gel scaffolding construct.

SEM was used to image the channels (FIG. 5). The bacterial cellulose channels were then endothelialized by perfusion of HUVECs through a bioreactor system.

Results:

SEM confirmed that micro channels were formed after introducing the micro channel construct. FIG. 5 shows an SEM image of a microchannel in bacterial cellulose gel scaffolding material. Histology and H&E staining verified the channels were lined with a confluent layer of endothelial cells. Imaging also confirmed endothelial cells lining the lumen of microchannels in a construct made with bacterial cellulose scaffolding material (not shown).

Conclusion:

Bacterial cellulose and fibrin have both been shown to support channel fabrication through SEM images. In addition, H&E staining has shown that the bacterial cellulose channels were endothelialized to create a prevascularized scaffold to support growth of other cellular networks such as fibroblasts and breast cancer cells. Therefore, both bacterial cellulose and fibrin represent promising scaffolding materials for construction of the prevascularized, 3D co-culture model biomaterial for mimicking human breast cancer environments.

Example 2—bioreactor with 3D vascularized tissue constructs with gel matrix scaffolds

Example 1 above describes successful creation of prevascularized 3D volumes within hydrogel biomaterials; the present example describes growth of mammalian cells

on scaffolds of the present disclosure and construction of bioreactors for the growth, maintenance, and observation/analysis of the tissue constructs.

The tissue constructs of the present example included human breast cancer cells. Two biomaterials were selected for the creation of the prevascularized scaffolds to support breast cancer cells: bacterial cellulose and fibrin gel. As described in example 1, above, these materials were successfully prevascularized with microchannels less than about 250 μm in diameter, and these microchannels were seeded with vascular endothelial cells demonstrating that the microchannels can support a confluent vascular endothelial layer. The present example demonstrates further seeding the 3D prevascularized tissue constructs with breast cancer cells and that these tissue constructs of the present disclosure can be continuously perfused in a flow bioreactor. This example demonstrates that such constructs and bioreactors can serve as the basis for development of a viable 3D co-culture that supports breast cancer epithelial cells, breast fibroblasts, and vascular endothelial cells.

Bioreactor design

FIG. 2 is a schematic drawing of the tissue construct chamber of a bioreactor of the present disclosure, as used in the present example, including a 3D vascularized tissue construct within the chamber. A cylindrical flow-through bioreactor as illustrated in the schematic of FIGS. 3 and as shown in the image of FIGS. 4A and 4B was constructed of polycarbonate in order to subject the micro-channels to pulsatile flow with culture media. The bioreactor was designed so that the prevascularized disc-shaped biomaterial could be mounted into a larger disc-shaped seat and placed inside the cylindrical flow-through chamber. The biomaterial and the seat represent a partition between the upstream and downstream flow, thus forcing media to pass through the array of micro-channels. Two lids sealed the bioreactor and enabled the upstream silicone tubing to be connected to the pump and the downstream tubing to act as a return to the reservoir. As described in Example 1, above, micro-channels for bacterial cellulose were formed around an array of 250 μm diameter wires, whereas micro-channels for fibrin were formed by punching the array into the scaffold after gelation. A stainless steel sheet with dimensions of 5 mm x 5 mm x 1 mm was used as the micro-channel construct base. Scanning electron microscopy confirmed that microchannels in

bacterial cellulose and fibrin were formed after introducing the micro-channel constructs. H&E staining showed a confluent layer of endothelial cells in the bacterial cellulose channels as well. However, the bacterial cellulose channels were irregular in shape and had uneven and funnel shaped channel openings. A multi-culture of human breast cancer cells (MDA-MB-231) and human breast fibroblasts (HT1080) were seeded into the fibrin scaffolding constructs and successfully grown and maintained in culture for 2 weeks.

3D Microphysiologic Bioreactor

Media flow through each prevascularized tissue construct bioreactor system is provided by commercially available high performance micropumps. These micropumps are suited to deliver precise flow of media to each tissue chamber. The micropump will perfuse the tissues with media specific to the tissue type. The total flow through each 3D tissue is uniformly distributed through each cylindrical channel within the tissue. Flows are governed by the Navier-Stokes equations, which can be simplified in microfluidic systems as the ratio of the inertia terms to the viscous terms (characterized by the Reynolds number Re) becomes negligible ($Re \ll 1$). This results in applying the Stokes equation to estimate microchannel pressure gradients:

$$0 = -\nabla p + \mu \nabla^2 \vec{u}$$

where p is pressure, u is fluid velocity, and μ is the dynamic viscosity of the media. In the case of cylindrical microchannels, a parabolic flow develops and the relation for shear stress can be described by the Hagen-Poiseuille equation:

$$\tau = \frac{4\mu Q}{\pi r^3}$$

Where τ is the fluid of media in the channel shear stress at the channel wall, Q is the volumetric flow rate, r is the radius of the channel and μ is the dynamic viscosity of the media. For the purpose of estimating shear stress at the walls of the microchannels, the media will be assumed to be single-phase Newtonian, rigid wall boundary with no slip at the wall.

Microchannels are cast within the tissue construct as described above and the tissue is perfused with media using the micropump. For a HuBiogel construct of 10 mm

diameter and 3 mm thick, with a 20 x 20 mm array of 250 micron diameter microchannels (total = 400), if each microchannel is 0.250 mm in diameter, then the total cross sectional area is $400(\pi r^2) = 400(\mu\pi.125^2) = 20 \text{ mm}^2$. The total volume of media contained within the microchannel system is about 60 mm^3 or 60 microliters. A mean volumetric flow rate (in the case of pulsatile flow from the peristaltic pump) of 60 microliters per minute yields a wall shear stress of approximately 8-10 dynes/cm² within each channel.

Example 3—3D vascularized tissue constructs with porous solid and gel matrix combination scaffolds

Cell culture using matrices to enhance cell growth is well known (e.g. Matrigel, HuBiogel). 3D cell culture is a rapidly advancing field where, for example, tumor cells can be grown that represent more closely the tumor microenvironment found in an in-vivo setting. This latter fact has led to an increased use of these 3D cell cultures to be used in a variety of drug screening assays. However, one of the problems in using the 3D and/or matrigel approach is that the spheroids formed in this manner can form necrotic cores and can shrink as they grow to a useable size, at least partially due to the lack of access to media including nutrients, oxygen, etc.

The examples above demonstrate the potential of forming 3D vascularized tissue constructs to support growth of cellular networks in a more physiologic environment. The present example demonstrates using a variety of novel materials to act as scaffolds for a variety of cell culture applications. The applications of these materials and this technology could include growth of tumor cell cultures and co-cultures without the need for a gel support or in combination with gel support to enhance structural integrity. The use of such materials also can also support the growth of physiologically relevant microphysiological systems (e.g. miniature organs or disease models (e.g., breast tumor models) to be used in place of animals during drug development) and as a mechanism to create potential synthetic blood vessels in the form of endothelialized microchannels through one or more of these materials.

The scaffolding materials used in the present example include a variety of aerogels obtained from Southern Research™ and commercially available materials in

the form of a reticulate vitreous carbon (RVC) (FIG. 6) having various pore sizes. RVC, also known as glassy carbon foam and available under the trade name Ultrafoam™ was obtained from Ultramet™, Pacoima, CA. Aerogels/Solgels are made according to a process where glass beads, aerogel, or nanofibers are coated with amphiphile and foamed in an aqueous solution. Solgel is added as a locking agent to hold the foam in place. The solgel can be thermally removed by heating to 600 degrees C. Alginate or gelatin can also be used as a locking agent. An aerogel used in the present example from Southern Research™ had a specific chemical composition of formaldehyde/resorcinol/amphiphile (gallic acid, ethyl ester) (FIGS. 13A and 13B). Aerogels can be made according to the process described in the following publications (both of which are incorporated herein by reference): Pekala, R.W. et al., "Resorcinol-Formaldehyde Aerogels and Their Carbonized Derivatives." 1989. American Chemical Society Division of Polymer Preprints. **30**: 221-223; and Pekala, R.W., et al., "Carbon Aerogels for Electrochemical Applications." 1998. Journal of Non-Crystalline Solids **225**: 74-80.

Experimental conditions

Medium: DMEM with 10% FBS and 1% PSG, Plate: 12 well cell culture cluster plate (Corning #3513), Cell line: breast cancer MDA-MB-231 (RFP stable line), Cell seeding: 250,000 cells/well/2ml of medium, Incubation: 37°C and 5% of CO₂, Medium change: every 2-3 days, Moved the aerogels into a new plate on day 8.

FIG. 7 represents a particle stabilized foam. Incorporated into the foam were 3M silica microbubbles. Resorcinol-formaldehyde was used as a matrix to strengthen the RVC foam. In this Example, the foam was incubated with breast cancer cells.

Furthermore, these constructs were successfully sectioned these materials in the normal manner for histopathology, and it was possible to employ other standard cellular and molecular assessment protocols of cell and tissue function. Processing the samples using conventional H&E demonstrates that cells have managed to infiltrate the individual pores and remain viable over a period of time.

All scaffolds prepared in this example supported viability of various cell types in appropriate physiological media, O₂/CO₂ environment, at 37 degrees. FIGS. 8-10 are images taken of RVC foam supporting growth of MDA-MB-231 breast cancer tumor

cells grown on RVC 45 pores per inch (ppi) at different days. FIG. 12 shows MDA-MB-231 cell grown on RVC 65 ppi. FIG. 11 represents a control, showing an image of the MDA-MB-231 cells grown on a flat substrate. FIG. 7 shows MDA-MB-231 cells grown on the particle stabilized foam described above. FIG. 13A shows the MDA-MB-231 cells grown on the aerogel scaffolding material described above.

Example 4—tissue constructs and bioreactor for RVC-based scaffold 3D vascularized tissue constructs

The present example demonstrates that an extracellular matrix scaffold has been developed to mimic the native extracellular matrix and includes growth of relevant cell types (e.g., human breast cancer epithelial cells and human breast fibroblasts) along with the prefabricated vascular network (prevascularization). These systems are intended to support long-term growth, recapitulate physiological tissue function, and accurately model response to treatment. The use of these 3D vascularized tissue constructs that can support growth of reproducible tissue volumes will transform breast cancer drug development by providing reliable, cost-effective models that can more accurately predict therapeutic efficacy than current preclinical *in vivo* and *in vitro* models.

EXPERIMENTAL METHODS

Perfusion Bioreactor Design

Two versions of the perfusion bioreactor were been designed and fabricated. The first, a disc shape, is compatible with a 12 well-plate format (FIG. 15A). The second, a rectangular volume, is suitable for confocal imaging (FIG. 15B). Endothelial cell (EC)-rich media was pumped through the micro-channels in a closed-loop system. The peristaltic pump induced unsteady flow. A syringe pump was used for one way flow of short-term experiments. In both configurations, the scaffolds acted as a divider between upstream and downstream flow forcing the media to flow through the fabricated micro-channels in the scaffolds.

Scaffold & Micro-channel Fabrication

Scaffolds were either composed of reticulated vitreous carbon (RVC) and collagen measuring 10 mm in diameter x 3 mm in height or composed of RVC, collagen,

and Matrigel measuring 10 mm in width x 5 mm in length x 2.4 mm in height. Prior to gelation, 400 micron diameter stainless steel rods were soaked in 25% glutaraldehyde, air-dried, and then injected into the RVC foam pores length-wise. For the RVC/collagen scaffolds, a solution of 1.5 mg/ml collagen was injected into the RVC pores. For the RVC/collagen/Matrigel scaffolds, a solution of 1.9 mg/ml collagen containing 10% Matrigel was composed by mixing 14.7% (v/v) of DMEM/10% FBS, 1.9 mg/ml collagen, 10% (v/v) of 10X media, 10% (v/v) of Matrigel and 0.524 M of sodium bicarbonate. The collagen/Matrigel solution was injected into the RVC pores.

For gelation of collagen/matrigel mixed scaffolding, frozen Matrigel and collagen was thawed in ice. Cell culture media and sodium bicarbonate were kept cold on ice as well. The following components were mixed in the stated order in a 2ml microcentrifuge tube for creation of a 1.9 mg/ml concentration collagen solution containing 10% (v/v) Matrigel: 1) Media or deionized water – 137 μ l, collagen – 633 μ l (drop-wise), Matrigel – 100 μ l, 10X volume of media - 100 μ l, sodium bicarbonate – 30 μ l (drop-wise). The tube was gently inverted until color is homogeneous. Using a 1ml syringe, 0.3 ml of the liquid solution was withdrawn. A 27 Gauge needle was added to the end of the syringe and solution was inserted into RVC samples having microchannel construct in place, being careful not to touch the microchannel construct wires with the liquid. The PDMS tube/RVC/matrix construct was placed in a petri dish and wrapped with parafilm. A vacuum was used to de-gas and remove bubbles by allowing the vacuum to get down to at 4 inHg. Samples were moved to an incubator for 45 minutes to allow for gelation of Matrigel and collagen.

After gelation of all scaffolds, the rods were gently removed to form the micro-channels, which are shown in the images of FIGS. 14A and 14B.

Bioreactor Version 1 - Micro-channel Endothelialization

RVC/collagen scaffolds were placed in the bioreactor. To statically seed the fabricated micro-channels with endothelial cells, 2.44×10^8 of rat brain endothelial cells (RBEC) were cultured and plated on top of each scaffold. The bioreactor was sealed and placed into the incubator (37°C, 5% CO₂) for 30 minutes to statically seed the micro-channels with RBECs. The primed tubing was hooked up to the bioreactor, reservoir, and peristaltic pump, the pump was turned on, and the bioreactor was left in

the incubator (37°C, 5% CO₂) overnight to dynamically seed the micro-channels with RBECs. Then, the bioreactor was disassembled and the scaffold was formalin-fixed, processed, paraffin wax-embedded, and sectioned with a microtome. The sections were H&E stained. Hematoxylin stained the nuclei purple and eosin stained the cytoplasm pink.

Bioreactor Version 1 - Co-culture Viability

The collagen/RVC scaffold was prepared as before, but the DMEM/10% FBS media contained a cell suspension of 7.5×10^6 cells/ml human breast cancer epithelial cells (MDA-MB-231) and 2.5×10^6 cells/ml human breast fibroblasts (F080). In addition, the gels were gelled in a 12-well plated instead of the perfusion bioreactor. After 45 minutes in the incubator to allow for gelation, 1 ml of media was placed on top of the scaffolds. The scaffolds were left in the incubator for 3 days and then they were sectioned and H&E stained.

Bioreactor Version 2 – Micro-channel Endothelialization

RVC/collagen/Matrigel scaffolds were placed in a 48-well plate. To statically seed the fabricated micro-channels with endothelial cells, RBEC-rich media (16.1×10^6 cells/scaffold) was added in the 48-well plate housing the scaffolds. These scaffolds were placed in the incubator (37°C, 5% CO₂) for 3 days to allow for static seeding of the micro-channels.

RESULTS & DISCUSSION

H&E staining confirmed that the micro-channels in RVC/collagen and RVC/collagen/Matrigel were formed after introducing the stainless steels rods prior to gelation and that the collagen and collagen/Matrigel both infiltrated into the RVC foam pores. Additionally, H&E staining showed a monolayer of endothelial cells lining the RVC/collagen micro-channels. Finally, H&E has shown survival of a co-culture of cells (e.g., MDA-MB-231 and F080s) in the collagen scaffolds.

FIGS. 14A-14D show images of vascularized scaffolding constructs of the present example. A 45 ppi collagen/RVC scaffold (1.5 mg/ml collagen/RVC) with two 400 micron diameter micro-channels shown penetrating through the 4mm thick RVC/collagen scaffold is shown in FIG. 14A. FIG. 14B shows an image of a collagen/Matrigel/RVC scaffold (1.9 mg/ml collagen/Matrigel/RVC, 45 ppi) with three

400 micron diameter micro-channels through the scaffold. FIG. 14C is an image of a section through a collagen/RVC/Matrigel scaffold material with the microchannels visible as the open circular shaped areas, and portions of the RVC scaffolding material visible as the black portions. FIG. 14D is an image of a section (20um) through gel material showing a cross-section of a single microchannel with endothelial cells lining the interior surface of the microchannel.

These results demonstrate the successful endothelialization of fabricated micro-channels in a 3D volume under conditions of flow. Fluid volumetric flow rates through these 3D constructs and fluid shear stress, in particular cyclic shear stress, at the walls of these channels have not yet been calculated. Since exposure of the endothelium, a monolayer of endothelial cells lining blood vessel walls, to oscillating fluid shear stresses and circumferential cyclic strain from the pulsatile blood flow maintains the physiological state of the blood vessels, mimicking or approximating these stresses in the bioreactor help to create physiological biomaterial/cell scaffolds [5]. In addition, endothelial transport of oxygen, nutrients, waste, and candidate therapeutics is dependent in part on the fluid shear stress that is imparted at the endothelium. Thus, these micro-channels not only provide a conduit for fluid media, cell culture, growth factors, and the like, but it is also hoped that they can develop additional capillary functions such as extracting oxygen from fluid media.

CONCLUSIONS

Prevascularized engineered tissues have the potential to revolutionize tissue replacement for diseased or traumatized tissues [6]. In addition to tissue replacement, the prevascularized 3D constructs also have the potential to mimic multiple disease states for drug development.

This example demonstrates successful creation of 3D volumes of RVC/collagen and RVC/collagen/Matrigel exceeding the diffusion distance of oxygen by prevascularizing these scaffolds. In the case of collagen, micro-channels were created and successfully endothelialized within the constructs, and a co-culture of cells was grown within the vascularized constructs. These results set the stage for highly-defined 3D tissue volumes that are perfused and can be used for the evaluation of anti-cancer therapies using primary human cell lines or cells extracted from breast cancer patients.

Future work will include complete endothelialization of RVC/collagen/Matrigel scaffold micro-channels, growth of MDA-MB-231s and F080s in RVC/collagen/Matrigel scaffolds, and quantification of fluid mechanical parameters of micro-channel wall shear stress.

In regard to the discussion herein including the Examples above and the claims, it should be noted that ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a concentration range of “about 0.1% to about 5%” should be interpreted to include not only the explicitly recited concentration of about 0.1 wt% to about 5 wt%, but also include individual concentrations (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%) within the indicated range. The term “about” can include $\pm 1\%$, $\pm 2\%$, $\pm 3\%$, $\pm 4\%$, $\pm 5\%$, $\pm 6\%$, $\pm 7\%$, $\pm 8\%$, $\pm 9\%$, or $\pm 10\%$, or more of the numerical value(s) being modified. In addition, the phrase “about ‘x’ to ‘y’” includes “about ‘x’ to about ‘y’”.

It should be emphasized that the above-described embodiments of the present disclosure are merely possible examples of implementations, and are set forth only for a clear understanding of the principles of the disclosure. Many variations and modifications may be made to the above-described embodiments of the disclosure without departing substantially from the spirit and principles of the disclosure. All such modifications and variations are intended to be included herein within the scope of this disclosure and protected by the following claims.

REFERENCES

- All of the references are incorporated herein in pertinent part.
1. Birgersdotter A, Sandberg R, Ernberg I: Gene expression perturbation in vitro--a growing case for three-dimensional (3D) culture systems, *Semin Cancer Biol* 2005, 15:405-412

2. "FDA Issues Advice to Make Earliest Stages of Clinical Drug Development More Efficient." FDA. Jan 2006. <
<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108576.htm>>
3. "U.S. Breast Cancer Statistics." BreastCancer.org. Oct 2012. <
http://www.breastcancer.org/symptoms/understand_bc/statistics>.
4. Kim SS, Utsunomiya H, Koski JA, Wu BM, Cima MJ, Sohn J, Mukai K, Griffith LG, Vacanti JP: Survival and function of hepatocytes on a novel three-dimensional synthetic biodegradable polymer scaffold with an intrinsic network of channels, *Ann Surg* 1998, **228**:8-13
5. Davies, P.F. 1995. "Flow Mediated Endothelial Mechano- transduction." *Physiological Reviews*. **75**: pp.519-51.
6. Wu, X. et al. 2004. "Tissue Engineered Microvessels on 3D Biodegradable Scaffolds Using Human Endothelial Progenitor Cells." *Am J Physiol Heart Circ Physiol*. **287**: pp.H480-7.
7. Pec, Martina et al. 2010. "Reticulated Vitreous Carbon: A Useful Material For Cell Adhesion and Tissue Invasion." *European Cells and Materials*. **20**: 282-94.
8. Pekala, R.W. et al., "Resorcinol-Formaldehyde Aerogels and Their Carbonized Derivatives." 1989. *American Chemical Society Division of Polymer Preprints*. **30**: 221-223.
9. Pekala, R.W., et al., "Carbon Aerogels for Electrochemical Applications." 1998. *Journal of Non-Crystalline Solids* **225**: 74-80.

Claims:

1. A three-dimensional (3D), engineered, vascularized tissue construct comprising:
 - a 3D, biocompatible scaffold material;
 - a 3D network of living cells within the scaffold material;
 - a plurality of microchannels extending through the construct, such that a substantial portion of the channels have an inlet at one surface of the construct and an outlet at an opposing surface of the construct, wherein the channels form a lumen for allowing passage of liquid through the construct; and
 - a plurality of endothelial cells at least partially lining the lumen.

2. The 3D vascularized tissue construct of claim 1, wherein the 3D biocompatible scaffold material comprises a solid, porous material, a gel matrix material, or a combination thereof.

3. The 3D vascularized tissue construct of claim 2, wherein the biocompatible scaffold material comprises a gel matrix material and further comprises a crosslinking agent, a gelling agent, or a combination thereof that increases the structural stability of the gel matrix material.

4. The 3D vascularized tissue construct of claim 1, wherein the gel matrix material is selected from the group of gel matrix materials consisting of: synthetic hydrogels, naturally-derived hydrogels, and a combination thereof.

5. The 3D vascularized tissue construct of claim 1, wherein the synthetic hydrogel is selected from the group consisting of: alginate, biocompatible polymer hydrogels, biocompatible copolymer hydrogels, polyethylene glycol (PEG) based hydrogels, and combinations thereof.

6. The 3D vascularized tissue construct of claim 1, wherein the naturally-derived hydrogel is selected from the group consisting of: collagen, fibrin, elastin, keratin, Matrigel™, bacterial cellulose, HuBiogel™, and combinations thereof.
7. The 3D vascularized tissue construct of claim 1, wherein the solid, porous, material is selected from the group consisting of: aerogels, particle stabilized biocompatible foams, reticulate vitreous carbon (RVC), natural electrospun polymers, synthetic electrospun polymers, and combinations thereof.
8. The 3D vascularized tissue construct of claim 1, wherein the biocompatible scaffold material comprises reticulate vitreous carbon and a gel matrix material selected from the group consisting of: Matrigel™, bacterial cellulose, collagen, fibrin, elastin, keratin, HuBiogel, and combinations thereof.
9. The 3D vascularized tissue construct of claim 8, wherein the biocompatible scaffold material comprises a combination of RVC, collagen and a second gel matrix material selected from Matrigel™ and HuBiogel.
10. The 3D vascularized tissue construct of claim 1, wherein the tissue construct is configured to be placed in a well-plate or a flattened parallel plate flow chamber.
11. The 3D vascularized tissue construct of claim 1, wherein the tissue construct is configured for placement on a confocal imaging device, a fluorescence imaging device, a phase contrast imaging device, or interchangeably on any of these devices.
12. The 3D vascularized tissue construct of claim 1, wherein the microchannels have a diameter of about 200 to about 450 microns.
13. The 3D vascularized tissue construct of claim 1, wherein the microchannels have a diameter of about 250 microns or less.

14. The 3D vascularized tissue construct of claim 1, wherein the cells comprise mammalian cells, wherein the cells are pathologic or healthy mammalian cells or a combination thereof.
15. The 3D vascularized tissue construct of claim 1, wherein the cells comprise cancer cells or a combination of cancer cells and non-cancerous cells.
16. The 3D vascularized tissue construct of claim 15, wherein the non-cancerous cells comprise fibroblasts, epithelial cells, human tissue cells, or a combination thereof.
17. The 3D vascularized tissue construct of claim 15, wherein the cells comprise breast cancer cells, and the 3D network of cells forms a breast cancer tumor.
18. The 3D vascularized tissue construct of claim 15, wherein the cells comprise breast cancer cells and non-cancerous breast tissue cells, and wherein the 3D network of cells forms a breast cancer tumor.
19. The 3D vascularized tissue construct of claim 18, wherein the breast cancer cells comprise human breast cancer epithelial cells and wherein the non-cancerous breast tissue cells comprise human breast fibroblasts.
20. A three-dimensional (3D) vascularized biocompatible scaffold for supporting in vitro, 3D tissue culture comprising:
 - a 3D, biocompatible scaffold material comprising a solid, porous material, a gel matrix material, or a combination thereof, wherein the solid, porous material is chosen from the group consisting of: aerogels, reticulate vitreous carbon, particle stabilized foam, and combinations thereof, and wherein the gel matrix material is chosen from the group of gel matrix materials consisting of: synthetic hydrogels, naturally-derived hydrogels, and a combination thereof; and
 - a plurality of channels extending through the scaffold, such that a substantial portion of the channels have an inlet at one surface of the scaffold and an outlet at an

opposing surface of the scaffold, wherein the channels form lumen for allowing passage of liquid through the scaffold.

21. The 3D vascularized biocompatible scaffold of claim 20, further comprising a plurality of endothelial cells at least partially lining the lumen.

22. The 3D vascularized biocompatible scaffold of claim 20, wherein the gel matrix material comprises one or more hydrogels selected from the group of consisting of: synthetic and naturally derived hydrogels consisting of: collagen, fibrin, Matrigel™, bacterial cellulose, HuBiogel™, alginate, polymer based hydrogels, copolymer based hydrogels, polyethylene glycol (PEG) based hydrogels, elastin, and keratin.

23. The 3D vascularized biocompatible scaffold of claim 20, wherein the solid, porous, material is selected from the group consisting of: aerogels, particle stabilized biocompatible foams, reticulate vitreous carbon (RVC), natural electrospun polymers, synthetic electrospun polymers, and combinations thereof.

24. The 3D vascularized biocompatible scaffold of claim 20, wherein the microchannels have a diameter of about 200 to about 450 microns.

25. A three-dimensional (3D), *in vitro*, vascularized cancer model comprising a 3D tissue construct comprising:

a biocompatible scaffold material;

a 3D network of living cells within the scaffold material, wherein the network of cells comprises cancer cells or a combination of cancer cells and non-cancerous cells within the scaffold material;

a plurality of channels extending through the construct, such that a substantial portion of the channels have an inlet at one surface of the construct and an outlet at an opposing surface of the construct, wherein the channels form a lumen for allowing passage of fluid media through the construct; and

a plurality of endothelial cells at least partially lining the lumen.

26. The 3D vascularized cancer model of claim 25, wherein the model is a human breast cancer model and wherein the network of living cells comprises human breast cancer tumor cells and non-cancerous human breast fibroblast cells.
27. The 3D vascularized cancer model of claim 26, wherein the breast cancer tumor cells form a spheroid.
28. A perfusion bioreactor comprising:
a three-dimensional (3D), engineered tissue construct comprising:
a 3D, biocompatible scaffold material;
a 3D network of living cells within the scaffold material;
a plurality of channels extending through the construct, such that a substantial portion of the channels have an inlet at one surface of the construct and an outlet at an opposing surface of the construct, wherein the channels form lumen for allowing passage of fluid media through the construct; and
a plurality of endothelial cells at least partially lining the lumen;
a tissue chamber configured to house the tissue construct such that the tissue construct forms a barrier between upstream and downstream flow of media through the chamber directing flow of media through the channels of the tissue construct, wherein the chamber has at least one input portal upstream of the location of the tissue construct and at least one output portal downstream of the location of the tissue construct; and
at least one pump to control flow of media through the tissue chamber.
29. The perfusion bioreactor of claim 28, wherein the at least one pump is selected from the group consisting of: micropumps, syringe pumps, peristaltic pumps, and combinations thereof.

30. A method of making a three-dimensional (3D), vascularized, tissue construct *in vitro* comprising:

providing a 3D vascularized biocompatible scaffold, wherein the scaffold comprises: a 3D, biocompatible scaffold material and a plurality of channels extending through the scaffold, such that a substantial portion of the channels have an inlet at one surface of the scaffold and an outlet at an opposing surface of the scaffold, wherein the channels form lumen for allowing passage of liquid through the scaffold;

seeding the lumen with endothelial cells, such that endothelial cells line at least a portion of the lumen;

seeding the scaffold with cells of at least one tissue type;

perfusing the scaffold with cell culture media; and

incubating the seeded scaffold,

wherein a 3D network of cells of the at least one tissue type grows within the scaffold.

31. The method of claim 30, wherein the 3D, biocompatible scaffold material comprises a solid, porous material, a gel matrix material, or a combination thereof, wherein the solid, porous material is chosen from the group consisting of: aerogels, reticulate vitreous carbon, and particle stabilized foam, and wherein the gel matrix material is chosen from the group consisting of: synthetic hydrogels, naturally-derived hydrogels, and a combination thereof.

32. The method of claim 31, wherein the gel matrix material comprises one or more hydrogels selected from the group of synthetic and naturally derived hydrogels consisting of: collagen, fibrin, Matrigel™, bacterial cellulose, HuBiogel™, alginate, polymer based hydrogels, copolymer based hydrogels, polyethylene glycol (PEG) based hydrogels, elastin, and keratin.

33. The method of claim 30, wherein at least one type of cells are cancer cells.

34. The method of claim 33, wherein the cells comprise human breast cancer tumor cells or a combination of human breast cancer tumor cells and human breast fibroblast cells.

35. A method of making a three-dimensional (3D), vascularized scaffolding material comprising:

providing a 3D, biocompatible scaffold material; and

forming a plurality of microchannels in the scaffold material with a microchannel construct, wherein the channels extend through the scaffold, such that a substantial portion of the channels have an inlet at one surface of the scaffold and an outlet at an opposing surface of the scaffold, wherein the channels form lumen for allowing passage of liquid through the scaffold.

36. The method of claim 35, wherein the microchannel construct comprises a plurality of rods or wires for forming the channels.

37. The method of claim 36, wherein the plurality of rods or wires have an individual diameter of about 200 to about 400 microns.

38. The method of claim 35, wherein the 3D, biocompatible scaffold material comprises a solid, porous material, a gel matrix material, or a combination thereof, wherein the solid, porous material is chosen from the group consisting of: aerogels, reticulate vitreous carbon, and particle stabilized foam, and wherein the gel matrix material is chosen from the group consisting of: synthetic hydrogels, naturally-derived hydrogels, and a combination thereof.

39. The method of claim 38, wherein the gel matrix material comprises one or more hydrogels selected from the group of synthetic and naturally derived hydrogels selected from the group consisting of: collagen, fibrin, Matrigel™, bacterial cellulose, HuBiogel™, alginate, polymer based hydrogels, copolymer based hydrogels, polyethylene glycol (PEG) based hydrogels, elastin, and keratin.

40. The method of claim 38, wherein the biocompatible scaffold material comprises a gel matrix material, and wherein the microchannel construct is inserted into the scaffold material before the gel matrix material is cured and is removed from the scaffold material after the gel matrix material is cured.

41. A method of screening a test compound comprising:
providing a three-dimensional (3D), engineered, vascularized tissue construct comprising: a 3D, biocompatible scaffold material; a 3D network of living cells of a tissue of interest within the scaffold material; a plurality of microchannels extending through the construct, such that a substantial portion of the channels have an inlet at one surface of the construct and an outlet at an opposing surface of the construct, wherein the channels form lumen for allowing passage of liquid through the construct; and a plurality of endothelial cells at least partially lining the lumen;
exposing the 3D tissue construct to the test compound; and
monitoring ~~any~~ changes in the tissue construct after exposure to the test compound, wherein the changes are selected from the group consisting of histological, biochemical, and physiological changes, and a combination thereof.

42. The method of claim 41, wherein at least a portion of the cells within the 3D network of living cells comprises diseased cells and wherein the test compound comprises a drug candidate for treating the disease.

43. A method of screening a potential cancer therapeutic compound comprising:
providing a three-dimensional (3D), engineered, vascularized cancer tissue construct comprising: a 3D, biocompatible scaffold material; a 3D network of living cells within the scaffold material comprising cancer cells or a combination of cancer cells and non-cancerous cells; a plurality of microchannels extending through the construct, such that a substantial portion of the channels have an inlet at one surface of the construct and an outlet at an opposing surface of the construct, wherein the channels form lumen for allowing passage of liquid through the construct; and a plurality of endothelial cells at least partially lining the lumen;
exposing the 3D cancer tissue construct to a test compound; and
detecting changes in growth or viability of the cancer cell network after exposure to the test compound, wherein a decrease in growth or viability of the cancer cells indicates the test compound is a potential breast cancer therapeutic compound.
44. The method of claim 43, further comprising detecting toxicity of the cancer therapeutic compound as measured by histological, biochemical, physiological changes, or a combination thereof, of the cell network.
45. The method of claim 43, wherein the cancer cells are breast cancer cells.
46. The method of claim 43, wherein the network of cells includes breast cancer cells and non-cancerous breast tissue cells.

47. A bioreactor network comprising an array of interconnected bioreactors and at least one pump to control flow of media through the bioreactors, wherein the bioreactors in the array are in fluid communication with each other, and wherein each bioreactor comprises:

a three-dimensional (3D), engineered tissue construct comprising:

a 3D, biocompatible scaffold material,

a 3D network of living cells within the scaffold material,

a plurality of channels extending through the construct, such that a substantial portion of the channels have an inlet at one surface of the construct and an outlet at an opposing surface of the construct, wherein the channels form lumen for allowing passage of fluid media through the construct, and

a plurality of endothelial cells at least partially lining the lumen; and

a tissue chamber configured to house the tissue construct such that the tissue construct forms a barrier between upstream and downstream flow of media through the chamber directing flow of media through the channels of the tissue construct, wherein the chamber has at least one input portal upstream of the location of the tissue construct and at least one output portal downstream of the location of the tissue construct;

wherein at least one bioreactor in the array contains cells from a different tissue type than the cells in at least one other bioreactor in the array.

ABSTRACT

Embodiments of the present disclosure provide for three-dimensional (3D), prevascularized, engineered tissue constructs, 3D prevascularized engineered tissue models of cancer, and bioreactors and bioreactor arrays including the tissue constructs. The present disclosure also provides methods of making the tissue constructs, methods of using the tissue constructs, methods of drug discovery using the tissue constructs and/or cancer models, and the like.